Podcasts about Pharma

Rebecca Bloom is a former employee benefits and executive compensation attorney who spent more than 25 years helping women navigate cancer, work, insurance, disability coverage, and financial survival. She is the founder and author of When Women Get Sick, a book built from decades inside the legal, workplace, and patient advocacy systems most people only discover after diagnosis.Bloom started in Big Law at Simpson Thacher handling employee benefits and compensation work she originally chose to pay off student loans. Then her mother was diagnosed with breast cancer. Suddenly the language she used in corporate law offices became the language of survival at home. Explanation of benefits forms. Coverage disputes. Second opinions. Disability protections. Medical leave. Bills no one could explain.That collision changed the direction of her life.In this episode, Bloom explains how serious illness quietly turns patients into unpaid administrators managing paperwork, logistics, financial risk, and emotional labor while trying to survive treatment. She breaks down how employer based health insurance shapes nearly every aspect of cancer care in America and why women often carry the invisible burden of protecting everyone else from discomfort while they themselves fall apart.The conversation digs into workplace power, the illusion of the healthcare “safety net,” caregiver exhaustion, and the class divide hiding underneath patient empowerment culture. Bloom explains why educated, insured women with resources still struggle to navigate healthcare bureaucracy and what happens to patients without those advantages.This episode explores cancer care, health insurance, employee benefits, patient advocacy, workplace protections, caregiving, and the structural incentives that force sick people to become project managers of their own survival.RELATED LINKSRebecca BloomWhen Women Get SickBay Area Cancer ConnectionsSimpson Thacher & BartlettFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sen. Ron Johnson says investigators found internal warnings that a federal vaccine-safety analysis could mask important signals. Why did officials allegedly ignore a second analysis, and why did most major news organizations skip the story? In this Good Morning Liberty interview, Senator Ron Johnson discusses his investigation into COVID vaccine safety surveillance, VAERS data, federal health agencies, informed consent, vaccine injuries, and declining trust in public-health institutions. Johnson describes searching 11 million pages of government records with six investigators. He says the documents show officials were warned about limitations in an algorithm and later received an analysis identifying multiple potential safety signals. VAERS reports alone do not prove causation, but Johnson argues that unusual patterns should have prompted further investigation and public warnings. The conversation also covers media incentives, pharmaceutical advertising, liability protection, medical freedom, congressional oversight, and why Johnson believes reducing federal power is essential to restoring liberty. Chapters 00:00 Why Senator Ron Johnson Says the Story Was Ignored 01:15 Eleven Million Pages and Six Investigators 02:00 The Algorithm Warning 04:15 Twenty-Five Potential Safety Signals 08:00 Informed Consent and Children 10:00 Swine Flu, VAERS, and Reporting Rates 12:00 Why Not Run Both Algorithms? 15:00 Media, Pharma, and the Narrative 20:00 Injury Recognition, Treatment, and Accountability 23:15 A Lonely Voice in Congress 28:30 What Happens Next? 31:45 One Change for Liberty Links Watch All Episodes: https://www.youtube.com/playlist?list=PLi78svKlBr_8o0dDOX8DxO_Wwxu6WYhhA Watch Host Favorites: https://www.youtube.com/playlist?list=PLi78svKlBr__Zu40RL7mWxCuOOe54zgy2 Join the Fed Haters Club @ https://www.goodmorningliberty.us/fedhatersclub Join GML: https://joingml.com All links @ https://gml.bio.link Subscribe, like the video, and tell us in the comments which part of Johnson's investigation deserves the most scrutiny. Share this interview with someone who still believes government agencies always investigate themselves honestly. Then leave Good Morning Liberty a rating and review on your podcast app.

Plus: Carl Icahn's company agrees to sell auto-service chain Pep Boys. And Ukraine strikes a deal with defense company BAE Systems to manufacture howitzers locally. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Vasanta Pundarika built her career inside healthcare investment banking before launching Lotuspring, an advisory firm focused on women's health and behavioral health. She spent nearly 20 years advising healthcare systems, treatment providers, and growth stage companies on mergers, financing, and operational strategy while watching the industry repeatedly misunderstand the people it claimed to serve.The conversation starts unexpectedly with anthropology, bread, and language. Vasanta explains how she spent years changing the pronunciation of her own name to make other people comfortable before eventually reclaiming it. That thread opens into a much larger discussion about adaptation, identity, and what institutions quietly train people to tolerate.From there, the discussion moves into behavioral health, women delaying care, and the invisible labor that healthcare business models routinely ignore. During COVID, Vasanta noticed men's behavioral health units refilled faster than women's units. The reason had nothing to do with demand. Women were still home managing caregiving responsibilities, children, aging parents, and households while their own mental health collapsed in the background.The episode examines what happens when healthcare companies become “snazzy big brands” before building real clinical substance underneath. Vasanta describes the tension between mission and margin inside healthcare startups, private equity backed care models, and behavioral health expansion. The conversation pushes on who benefits when healthcare scales aggressively, who absorbs the operational pressure, and how patient trust erodes long before executives notice it on a dashboard.They also discuss patient advocacy culture, anthropology as systems analysis, healthcare capitalism, prior authorization, investor language, and why some clinically excellent companies never survive long enough to scale.RELATED LINKSVasanta PundarikaLotuspringWomen's Health HorizonsSakhi for South Asian SurvivorsNACDPrinceton University Anthropology DepartmentFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're navigating through a myriad of transformative advancements reshaping the industry. From artificial intelligence-driven research breakthroughs to strategic acquisitions in emerging therapeutic areas, these developments are setting new benchmarks in drug discovery and patient care. **Strategic Acquisitions and Expansions:** Samsung Biologics' recent proposal to acquire Swiss CDMO Polypeptide for $1.8 billion marks a significant expansion into peptide production, underscoring the growing therapeutic importance of peptides. Their specificity and efficacy make them particularly appealing for metabolic disorders such as obesity. This acquisition reflects a strategic move to capture emerging market opportunities as demand for innovative metabolic treatments rises. Eli Lilly's bold $2.8 billion acquisition of Atai-Beckley highlights the pharmaceutical industry's shifting focus towards psychedelics. As mental health disorders like depression and PTSD become more prominent, psychedelics hold great promise for new therapeutic approaches. This acquisition may pave the way for further research and acceptance of psychedelics within mainstream medicine, offering new hope for patients. Another notable development is Tempus' acquisition of Personalisis for $1.5 billion. This move strengthens Tempus' cancer treatment portfolio by leveraging genomics-driven insights, emphasizing precision medicine's critical role in oncology. **AI Integration and Technological Innovation:** Bristol Myers Squibb is doubling down on AI integration by expanding its collaboration with Nvidia to build what promises to be the most powerful AI supercomputer dedicated to life sciences. This development is pivotal as it signifies a deeper commitment to harnessing computational power in R&D. By accelerating drug discovery and optimizing clinical trial processes, AI stands to revolutionize how treatments are developed and tailored to individual patients. Overall, these developments indicate a dynamic phase characterized by technological innovation and strategic collaborations. The integration of AI into drug development processes stands out as a transformative force, promising enhanced efficiency and efficacy in bringing new treatments to market. **Regulatory Milestones and Clinical Trials:** In regulatory news, Takeda's Qdenga has achieved a milestone by becoming India's first approved dengue vaccine. This approval is crucial in addressing neglected tropical diseases, with significant implications for public health in regions where dengue is prevalent. By reducing dengue fever incidence, this vaccine could play a vital role in improving health outcomes in many tropical countries. Promising results have emerged from clinical trials across various therapeutic areas. 4D Molecular Therapeutics reported an 87% reduction in treatment burden for wet AMD using their gene therapy candidate 4D-150 in Phase 2b trials—demonstrating potential as a transformative approach with reduced intervention frequency. Latigo Biotherapeutics' Nav1.8 inhibitor LTG-001 outperformed Vicodin in Phase 2 trials for acute pain, offering a non-opioid alternative amidst the opioid crisis. Meanwhile, Regenxbio's five-year data on surabgene lomparvovec shows sustained efficacy in wet AMD and diabetic retinopathy—underscoring its potential as a long-term treatment option. **Financial Performance and IPO Activity:** Financially, Abbott exceeded expectations with strong sales from their device and diagnostic divisions, prompting an upward revision of their full-year profit forecast. This reflects sustained demand for innovative diagnostic solutions and medical devices—highlighting Abbott's strategic market positioning. The IPO landscape remains active with companies like Nuvox Therapeutics seeking to raise funds for advancing oxygen therapeutics targeting hypoxia-related diseases—showcasing renewed investor interest and confidence within biotech innovation. Latigo Biotherapeutics is preparing for an IPO to advance its pipeline, demonstrating a strategic response to the opioid crisis. By developing alternatives that minimize addiction risks while providing effective relief, Latigo underscores the industry's commitment to safer pain management solutions. Turning to clinical trials, Scribe Therapeutics plans a $96 million IPO to advance its CRISPR-based lipid-lowering therapies, marking significant interest in genetic solutions for cardiovascular diseases like hyperlipidemia. The precision offered by CRISPR technology could revolutionize treatment options for conditions contributing significantly to cardiovascular health burdens. **Geopolitical Influences:** Geopolitical factors are also influencing market dynamics, particularly in the UK biotech sector where IPO plans are being shaped by global uncertainties despite robust venture capital backing. This situation underscores the complex interplay between regional economic conditions and global investment trends in biotech innovation. As these trends continue unfolding across the industry landscape—from AI-driven research advancements to strategic acquisitions—the potential impact on patient care paradigms remains profound. These developments not only promise new possibilities within drug development but also influence broader healthcare delivery models aimed at improving patient outcomes globally.Support the show

Hello our Poison Friends! We are back to fill you in on some more shady deeds from Johnson & Johnson's past. We have another Pharma guest appearance in this one, because Amgen was also involved in the synthetic erythropoietin business. Erythropoietin is the hormone released by the kidneys that stimulates red blood cell production. RBCs are produced in the blood marrow within bones. It always amazes me how the various systems of the body team up to keep everything balanced. Unfortunately, anemia (low RBCs/hemoglobin) is a common issue with kidney diseases, those on dialysis, and cancer patients. As such, these pharmaceutical companies sought to create synthetic erythropoietin to sell to these groups of patients. They succeeded and the treatment made billions of dollars in sales over the years. Relieving the effects of anemia in those with these already taxing conditions sounds great, but there were a number of problems. As it turns out, an increase in the hormone (and RBCs as a result) can lead to clotting, strokes, and heart attacks. Even worse, one researcher called the drug Miracle-Gro for tumors. Hundreds of thousands of patients were likely killed as a result of the treatment and J&J's hiding of study results. Thank you to all of our listeners and supporters! We truly appreciate you all! Please feel free to leave a comment or send us a DM!Patreon:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/thepoisonersalmanac⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Merch-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://poisonersalmanac.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Poisoner's Almanac IG-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/poisoners_almanac?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Poisoner's Almanac TT-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@poisonersalmanacp?_t=ZT-8wdYQyXhKbm&_r=1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of industry-shaping events, reflecting the ever-evolving landscape of drug development, regulatory challenges, and strategic maneuvers. In a significant move within the sector, Jasper Therapeutics has merged with Kira Pharmaceuticals, a strategic decision aimed at expanding its footprint in autoimmune therapeutics. This merger brings to Jasper a valuable asset in KP-104, a dual-inhibitor with the potential to address rare diseases—an area of considerable unmet need. Such consolidations highlight an industry trend where companies seek to bolster their portfolios with promising candidates that can tackle complex medical conditions. The merger exemplifies how strategic expansions are becoming increasingly integral to maintaining competitive edges in the biotech arena. Turning to clinical trials, Takeda's Zasocitinib has demonstrated promising results for patients suffering from moderate-to-severe plaque psoriasis. In Phase 3 trials, a significant 75% of patients achieved clearance of scalp psoriasis. Zasocitinib operates as a TYK2 inhibitor, targeting the IL-23 pathway—a crucial mechanism in autoimmune diseases like psoriasis. This breakthrough promises to enhance patient care by providing a more effective treatment option for those struggling with difficult-to-treat psoriasis. On the regulatory front, Novartis' Fabhalta (Iptacopan) has gained FDA approval for its role in slowing kidney function decline in patients with primary immunoglobulin A nephropathy. As a small molecule complement inhibitor, Iptacopan introduces a novel treatment class for this autoimmune kidney disorder. This approval underscores ongoing innovation within nephrology and offers renewed hope for improved patient outcomes. Recent regulatory updates also saw Novartis securing full FDA approval for Fabhalta—an affirmation of progress in addressing immunoglobulin A nephropathy through innovative therapeutic options. Business development remains a driving force in shaping industry landscapes. The acquisition of Mission Therapeutics' AKI candidate MTX652 by Dimerix is a prime example. This $5 million deal, with potential milestones up to $292 million, reflects high stakes and ambitions to advance treatments for acute kidney injuries—a field with significant unmet medical needs. The integration of artificial intelligence continues to revolutionize drug discovery processes. Aqemia's collaboration with Sanofi highlights this trend, showcasing AI's crucial role in expediting drug development and uncovering novel therapeutic targets. Their partnership potentially worth $140 million underscores AI's transformative potential within pharmaceutical research. Notably, Nobel laureate Jennifer Doudna's foray into AI-powered protein design signifies an exciting intersection between gene-editing technology and artificial intelligence. Her involvement signals potential revolutions in drug discovery through enhanced precision in protein engineering. However, regulatory challenges persistently loom over the industry. Novo Nordisk and Alvotech have faced FDA scrutiny concerning manufacturing deficiencies—an issue that accentuates the importance of stringent quality control and operational excellence in biologics manufacturing. The American Society of Health-System Pharmacists (ASHP) report on U.S. drug shortages during Q2 2026 reveals vulnerabilities within supply chains, notably impacting oncology drugs. These shortages emphasize the critical need for robust strategies to ensure consistent drug availability for essential therapies. Furthermore, geopolitical dynamics are influencing pharmaceutical supply chains. A U.S. Senate bill aimed at increasing transparency highlights concerns over China's dominance in drug ingredient supplies—an issue necessitating strategic adjustments by globally operating companies. Elsewhere within the sector, GSK made headlines by discontinuing the development of its chronic cough treatment camlipixant following mixed Phase 3 trial results—a setback illustrating the critical nature of trial outcomes in determining drug viability and market potential. In market trends, biotech IPOs have surged during the first half of 2026—a sign of robust investor interest fueled by innovations and favorable funding environments despite associated market volatility risks. Strategic adjustments continue across companies with mergers and acquisitions leading to workforce reductions—projected layoffs exceeding 14,000 within biopharma during H1 2026—as organizations streamline operations or pivot towards more promising research domains. Lastly, Merck's FDA approval for an oral PCSK9 inhibitor marks a significant achievement in cardiovascular care—representing another stride forward in therapeutic innovation. In summary, these developments encapsulate a landscape defined by scientific pursuits yielding mixed results amidst evolving regulatory interactions and strategic realignments—all contributing towards innovative healthcare solutions while navigating complex industry dynamics.Support the show

Jordan and Nate open with a genuinely wild AI experiment: Nate ran his genetic data through an AI tool and got a full cognition, energy, and hormone report back. From there they dive deep into psychedelic therapy, celebrating RFK Jr.'s new HHS VA partnership researching psychedelics for veterans while flagging real concerns. Big Pharma is already circling, with Eli Lilly dropping billions to patent DMT based compounds, and the guys unpack a tragic Miami retreat case that shows why sketchy wellness grifters are just as dangerous as pharma control. They also roast a Wired writer who tried to "debunk" RFK's high protein advice by eating nothing but protein powders and pop tarts, dig into the mysterious diarrhea causing parasite showing up in lettuce, and cover a UK lab's synthetic fiber designed to hijack your GLP1 hormones. Rapid fire news on daylight saving time, baby formula ingredients, and a scary new screen time study rounds things out.

Industry money flows through regulators, nonprofits, and lawmakers, making real reform impossible without transparency and reduced political influence. #PharmaLobby #RegulatoryCapture #HealthcarePolitics

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to forge ahead, making significant strides in scientific advancements, regulatory approvals, and strategic business developments. These moves are reshaping the landscape of drug development and patient care. Starting with Merck & Co.'s recent FDA approval for Lipfendra, the world's first oral PCSK9 inhibitor, this marks a pivotal shift in managing hypercholesterolemia. Traditionally, PCSK9 inhibitors have been administered via injection, but Lipfendra offers a more convenient oral alternative. This could significantly improve patient adherence and outcomes by easing the administration process for those managing cholesterol levels. The drug's approval highlights a crucial advancement in cardiovascular treatment, with expectations of reaching peak annual sales of $5 billion, underscoring its market potential. In another significant development, Eli Lilly has entered the burgeoning field of psychedelic therapeutics with its acquisition of Ataibeckley for up to $3.8 billion. This move reflects a growing trend toward exploring novel therapeutic avenues for psychiatric disorders. Psychedelic compounds promise new hope for patients with depression and other mental health conditions where conventional therapies have shown limited efficacy. Eli Lilly's investment signals confidence in the transformative potential of psychedelics, which could revolutionize treatment paradigms for conditions like depression and PTSD. Turning to obesity treatment, Novo Nordisk's Wegovy pill has received European Commission approval for obesity and overweight adults. As a small molecule GLP-1 receptor agonist, semaglutide enhances satiety and reduces caloric intake. This development underscores the increasing focus on metabolic disorders and highlights the competitive landscape as companies race to dominate the weight management sector with innovative oral formulations. In oncology news, Merck & Co.'s Keytruda has achieved a milestone in becoming the first PD-1 inhibitor to demonstrate phase 3 benefits as a single agent in frontline mismatch repair-deficient endometrial cancer. This success not only reinforces Keytruda's role in oncology but also emphasizes the importance of precision medicine approaches targeting specific genetic mutations in cancer therapy. The industry is also seeing substantial financial maneuvers aimed at bolstering research capabilities and market reach. Johnson & Johnson has raised its 2026 financial guidance following Tremfya's impressive $2 billion revenue milestone with its IL-23 inhibitor for autoimmune diseases. Additionally, their strategic supply chain restructuring reflects efforts to enhance operational efficiency amid a broader U.S. manufacturing push. On the regulatory front, Johnson & Johnson received UK MHRA approval for Akeega in BRCA1/2-mutated metastatic prostate cancer, highlighting ongoing focus on precision medicine and targeted therapies in oncology. Meanwhile, Medtronic's recall of Harmony Catheter Delivery Systems due to safety concerns serves as a reminder of ongoing vigilance in medical device safety regulations. In clinical trial advancements, InnoCare Pharma's TYK2 inhibitor demonstrated efficacy in a Phase 2 trial for nonsegmental vitiligo, achieving its primary endpoint and paving the way for Phase 3 studies. This highlights TYK2 inhibition as a promising strategy for autoimmune diseases like vitiligo. Moreover, we witness movements towards public offerings with companies like Vogenx and Braveheart Bio aiming for IPOs to fund their respective drug development projects. These efforts underscore the continuous drive for capital to propel innovative therapies through clinical trials and towards commercialization. Finally, turning to regulatory updates, Sanofi has entered new chapters in mRNA patent litigation against Pfizer and Moderna, reflecting ongoing tensions over intellectual property rights within the high-stakes realm of COVID-19 vaccines and mRNA technology. The outcomes here could have far-reaching implications for mRNA-based therapeutics and vaccine development. As we look at these developments collectively, they illustrate a vibrant period for pharmaceutical and biotech companies innovating new treatments while navigating complex regulatory terrains. The implications for patient care are profound, with potential improvements in therapeutic options driven by new scientific breakthroughs and strategic industry shifts. These dynamics promise to reshape the future landscape of global healthcare delivery and pharmaceutical innovation as these trends continue to unfold.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the latest advancements shaping the future of drug discovery and patient care. Veradermics is making significant strides with its oral minoxidil formulation aimed at addressing female pattern hair loss. The mid-stage clinical trial results have analysts optimistic about Veradermics' potential to capture a significant portion of this underserved market. The oral form of minoxidil, traditionally used in topical Rogaine products, offers a novel delivery method that could enhance patient adherence and improve outcomes, marking an innovative leap in dermatological treatments. Johnson & Johnson is navigating the expiration of Stelara's patent protection with resilience, as Tremfya steps up to fill the revenue gap. With quarterly sales exceeding $2 billion, Tremfya underscores the critical role of strategic lifecycle management and robust product pipelines in weathering patent cliffs. This success highlights the necessity for pharmaceutical companies to sustain growth through a well-rounded portfolio that can absorb such impacts. In oncology, Celcuity has achieved a pivotal milestone with FDA approval for its small molecule inhibitor targeting breast cancer. This therapy promises blockbuster potential and could become a new standard-of-care, expanding treatment options for patients. The approval reflects ongoing innovation in oncology, where small molecules continue to play an essential role alongside biologics in advancing cancer therapies. AI-driven drug discovery is gaining traction as Insilico Medicine partners with CDMO Bora in a potentially $2.5 billion deal. This collaboration underscores AI's transformative potential in accelerating drug discovery and development processes. By leveraging artificial intelligence, Insilico aims to identify new drug candidates more efficiently, expediting their journey from bench to bedside. Kelun-Biotech is marking significant progress with its SAC-TMT program targeting non-small cell lung cancer (NSCLC), filling gaps left by Merck's phase 3 efforts. This development is crucial for providing more tailored therapeutic options in oncology, illustrating how advancements in drug development are driving forward personalized medicine. Roche continues its exploration of Alzheimer's disease treatments with a multifaceted approach that includes both amyloid and tau proteins as targets. While its phase 3 amyloid program is prominent, Roche's interest in tau protein highlights the complexity of tackling neurological disorders and the need for diverse therapeutic strategies. Meanwhile, Biogen remains steadfast in defending its anti-tau Alzheimer's candidate following mixed phase 2 results that showed slowed cognitive decline. Despite stock volatility, this endeavor illustrates the high-stakes nature of Alzheimer's research as companies pursue novel approaches to this challenging disease. Regulatory landscapes are also shifting as Johnson & Johnson halts development of an eye disease gene therapy after disappointing phase 2b results. This move reflects the inherent risks involved in gene therapy and underscores the necessity for thorough evaluation at each clinical stage. Medtronic's recall of its Harmony delivery catheter system due to potential detachment risks serves as a reminder of the paramount importance of safety and quality control in medical device manufacturing. Such recalls impact patient safety and emphasize regulatory vigilance over device reliability. In summary, these innovations demonstrate the dynamic nature of the pharma and biotech industries where cutting-edge science drives progress. Integrating AI into drug discovery, managing product lifecycles post-patent expiry, advancing personalized medicine, and maintaining regulatory diligence collectively shape a landscape focused on improving patient outcomes worldwide. Turning to recent scientific developments: Eli Lilly's presentation at AAIC 2026 on their anti-amyloid Alzheimer's drug Kisunla explores maintenance therapy possibilities once amyloid levels fall below a threshold. This potential shift could signify a paradigm change by extending therapeutic benefits and possibly improving long-term outcomes for patients with Alzheimer's. Biogen's advances with its anti-tau Alzheimer's therapy partnered with Ionis Pharmaceuticals further validate the tau hypothesis. The promising mid-stage data on their antisense drug Diranersen opens opportunities for other companies like Denali Therapeutics to explore similar avenues for treating neurodegenerative diseases. The industry is also witnessing a resurgence in biotech IPOs during 2026's first half, recovering from a sluggish 2025. This surge signals investor confidence in biotechnological innovation while providing capital for advancing research pipelines. Financial activities within the sector are robust as Attovia Therapeutics files for an IPO to fund its competitive pipeline against Sanofi's Dupixent. Meanwhile, Advancell's $315 million Series D funding supports advancing prostate cancer candidates into Phase 3 trials, backed by big pharma confidence in radiotherapy's potential. Lastly, regulatory transparency improves as the FDA resumes releasing drug rejection letters after a temporary pause—a move likely to influence future submissions significantly by offering clearer guidance on regulatory expectations. These developments collectively highlight how scientific innovation and strategic maneuvers transform pharmaceutical landscapes, promising profound impacts on patient care through advanced therapies and novel treatments worldwide. As these trends unfold, they reflect an industry increasingly reliant on technological integration and collaborations to drive future growth and innovation.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into an array of groundbreaking advancements and strategic movements reshaping the landscape of healthcare and medicine. Recent strides in Alzheimer's research have highlighted Biogen's promising Phase 2 clinical trial results for diranersen, an antisense oligonucleotide targeting the tau protein. Unlike traditional amyloid-targeting therapies, this approach offers a novel mechanism that could diversify treatment options for Alzheimer's patients. By addressing tau pathology, a critical feature of Alzheimer's disease, Biogen's findings may influence research trajectories and potentially lead to improved patient outcomes. In tandem with this, Biogen and Eisai have received FDA approval for a subcutaneous formulation of Leqembi (lecanemab), targeting amyloid-beta plaques. This new delivery method is poised to enhance patient compliance and accessibility, marking significant progress in broadening Alzheimer's treatment modalities. In oncology, AstraZeneca has entered into a substantial $1.5 billion licensing agreement with Dizal Pharmaceutical for lung cancer therapies. This strategic partnership emphasizes the importance of collaborative efforts in advancing cancer treatment and highlights the role of targeted therapies in addressing unmet medical needs. Additionally, Merck KGaA's Erbitux has secured European Commission approval for first-line treatment of BRAF V600E-mutant metastatic colorectal cancer. By focusing on specific genetic mutations, this approval illustrates the shift towards precision medicine, where treatments are tailored based on individual genetic profiles. The industry is also embracing advanced technologies such as artificial intelligence (AI) to enhance drug discovery processes. Chai Discovery's partnership with Novartis exemplifies this trend, as they focus on AI-driven therapeutic antibody discovery. Meanwhile, Ardigen and Veraxa Biotech's collaboration in optimizing T-cell engager and ADC drug discovery demonstrates AI's growing role in reducing timeframes and costs associated with bringing new therapies to market. Regulatory updates from the FDA seek to streamline registration rules to alleviate manufacturing burdens for biopharma companies, reflecting ongoing efforts to improve operational efficiencies in drug production. Additionally, new guidance on psychedelics indicates a regulatory openness that could stimulate innovation within neurological therapeutics. In other news, HUYABIO's Phase 3 trial results have shown promise for advanced skin cancer patients through a combination therapy involving Bristol Myers Squibb's Opdivo. This success underscores the potential of combination therapies to enhance treatment efficacy. Meanwhile, cell therapy is experiencing a transformative shift with Cellares' advancements in automating manufacturing processes. These innovations promise broader access to life-saving cell therapies by accelerating production timelines and reducing costs. Turning to business developments, Spero Therapeutics' $1.1 billion deal with Innovent Biologics marks a strategic pivot towards immune modulation therapies, highlighting the growing interest in autoimmune diseases. Concurrently, Avere Therapeutics' public listing via a reverse merger with NextCure and acquisition of an IL-23 drug signifies ongoing consolidation within the sector. On the regulatory front, Beckman Coulter's expansion of its Alzheimer's diagnostic portfolio through a CE mark for its p-tau217 assay enhances diagnostic capabilities crucial for early detection and management amid an aging global population. As we look globally, cities like Basel and Beijing are emerging as biotech hubs, attracting top talent and investments while fostering innovation. Amid these shifts, industry professionals are encouraged to adapt to evolving technological landscapes, particularly with AI poised to enhance decision-making processes and streamline clinical workflows. These developments illustrate a dynamic phase for pharma and biotech sectors where scientific breakthroughs are closely intertwined with strategic business decisions and regulatory advancements. As we continue to navigate these changes, the potential for delivering more effective treatments across various therapeutic areas is immense. Stay tuned as we bring you more insights into how these innovations are shaping the future of healthcare globally. Thank you for joining us at Pharma Daily; until next time.Support the show

China ist auf dem besten Weg, im Biotech-Sektor zu einem entscheidenden Player zu werden. Es investiert gezielt in eigene Forschung, Lizenzdeals und Patentanmeldungen schnellen in die Höhe. Droht dem Westen eine neue Abhängigkeit? Marie Mallinckrodt, Moritz Küpper, Claus Michelsen, Katrin Materna www.deutschlandfunkkultur.de, Weltzeit

This week on the Midweek Takeaway, Kevin Hornsby is joined by Jeremy Skillington and Cathal Friel from Poolbeg Pharma to discuss the company's latest clinical milestone after dosing the first patient in its Phase II trial for POLB 001.The discussion covers how the treatment is designed to prevent cytokine release syndrome (CRS) in patients receiving cancer immunotherapies, the significance of Poolbeg's partnership with Johnson & Johnson, the commercial opportunity in a multi-billion-dollar market, and why management has continued to back the company with significant personal investmentDisclaimer & Declaration of InterestThis podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.

Brad Power spent years advising major corporations on systems design, process engineering, and decision making before lymphoma shoved him into the patient side of American healthcare. Instead of accepting the experience at face value, he started reverse engineering the machinery around cancer itself. Brad is the founder of Cancer Patient Lab and Open Cancer AI, two projects built around a blunt reality most patients discover too late: the healthcare system rewards people who know how to navigate it. Everyone else risks getting steamrolled by information asymmetry, insurance barriers, administrative friction, and institutional incentives designed around efficiency instead of human survival.The conversation starts with Harvard Business Review and Tumblr blogs before moving directly into the darker architecture underneath modern cancer care. Power explains how hospitals optimize for throughput, how insurance companies reward operational consistency over personalized medicine, and why many patients quietly end up needing a crash course in oncology, reimbursement policy, and behavioral psychology while fighting for their lives.The discussion digs into CAR-T therapy, functional testing, AI assisted decision support, and the growing collision between personalized medicine and standardized care pathways. Power argues that engaged patients often get better outcomes because they learn how to push for off guideline treatments, contest denials, and ask smarter questions. The counterpoint lands hard: patients should never have needed to become experts in the first place.The episode also explores the cultural consequences of AI entering cancer care. OpenAI advertising, data privacy, trust erosion, pharmaceutical influence, and “agentic AI” all collide inside a healthcare economy already drowning in distrust. Power sees artificial intelligence as a force multiplier for patient literacy and access. The larger system still decides who gets approved, who gets delayed, and who gets left behind.By the end, the conversation lands exactly where modern healthcare keeps forcing people to land: survival increasingly depends on learning how the machine works before the machine works on you.RELATED LINKSBrad PowerCancer Patient LabOpen Cancer AIHarvard Business ReviewResearch to the PeopleCAR T Cell TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The advancement of pharmaceutical manufacturing depends heavily on the research taking place in areas such as continuous manufacturing, automation, machine learning, and AI. The maturation of these technologies will foster improved process optimization, accelerate the development of medicines, and make manufacturing more efficient and reliable. This is the second part of our conversation with Thomas Roper, PhD, co-director of pharmaceutical engineering at Virginia Commonwealth University's Center for Pharmaceutical Engineering and Sciences and graduate program director for chemical and life science engineering. Roper discusses how graduate students in his research group have helped advance technologies ranging from computational fluid dynamics and process analytical technology to machine learning applications for process optimization. He also shares why he views AI as a powerful tool, not a replacement for people, and how it's preparing the next generation of scientists and engineers.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest news and insights that are shaping the landscape of patient care and drug development. The U.S. FDA has expanded the label for Pfizer and Astellas' Padcev, in combination with Merck's Keytruda, to include all muscle-invasive bladder cancer patients. This significant regulatory update broadens access to a combination therapy that merges an antibody-drug conjugate with a PD-1 inhibitor, offering enhanced treatment options for patients unable to tolerate cisplatin, a common chemotherapy drug. The decision marks a pivotal step forward in providing more inclusive and effective treatment regimens for bladder cancer. In Scotland, Roche's Columvi has been endorsed by the Scottish Medicines Consortium for use in treating relapsed or refractory diffuse large B-cell lymphoma. This approval highlights the growing importance of bispecific antibodies in oncology, which can simultaneously engage two different antigens to enhance anti-tumor responses. Such innovations underscore the ongoing transformation of cancer treatment through combination therapies. Across the Atlantic, Health Canada has approved Clinuvel's Scenesse for erythropoietic protoporphyria (EPP), a rare condition causing extreme light sensitivity. Scenesse acts as a melanocortin receptor agonist, offering photoprotection and improving quality of life for those affected by this debilitating disorder. On the business front, Bayer's strategic partnership with Apollo has secured a €3 billion equity deal for its long-acting reversible contraceptives business. This move underscores a growing emphasis on women's health and contraceptive innovation. Likewise, CMS and Insilico's collaboration aims to harness artificial intelligence for CNS drug discovery, promising to accelerate drug development through AI-driven target identification. Clinical trials continue to reveal promising developments. Eisai's Etalanetug is showing potential in reducing tau tangle biomarkers in dominantly inherited Alzheimer's disease. Similarly, Eisai and BioArctic's Leqembi subcutaneous autoinjector demonstrates comparable efficacy to its intravenous counterpart, potentially improving compliance and accessibility for early Alzheimer's patients through less invasive administration methods. Financially, Apnimed is planning an IPO to support its sleep apnea pill's commercial launch, while Velogene Biotechnology has secured Series A funding to advance its gene-editing platform. These financial activities highlight ongoing investments in innovative solutions aimed at addressing unmet clinical needs. Yet, challenges persist as well. The FDA has rejected Hengrui and Elevar Therapeutics' combination treatment for hepatocellular carcinoma for a third time, emphasizing the difficulties of meeting regulatory standards and demonstrating efficacy. Additionally, Germany's new healthcare cost-saving law has doubled pharmaceutical rebate rates, sparking industry concern over potential impacts on profitability and innovation investment. The regulatory landscape continues to evolve with the FDA proposing streamlined registration processes under the "hub-and-spoke" model to enhance transparency and security within supply chains. Meanwhile, recent FDA transparency actions have led to the release of 14 drug rejection letters, underscoring ongoing challenges in securing approvals due to stringent regulatory requirements. Geographically, emerging biotech hubs like Basel and Beijing are gaining prominence as global talent hotspots due to their conducive environments for research and development collaboration. These regions are becoming increasingly attractive for biopharmaceutical innovation. Amid fierce competition in obesity management solutions, Lilly's launch of its oral GLP-1 receptor agonist Foundayo faces stiff competition from Novo Nordisk's Wegovy pill. The race reflects broader trends toward developing patient-centric therapies that offer convenience alongside therapeutic efficacy. Intellectual property strategies are also evolving as companies employ new patent tactics to maintain competitive advantages in crowded markets. Safety remains a top priority as exemplified by Lupin Pharmaceuticals' recall of contaminated eye drops, highlighting ongoing challenges in ensuring product safety. Lastly, advancements in wearable technology offer promising improvements in patient care; however, integration into clinical practice is met with infrastructural hurdles—a sentiment echoed by healthcare professionals surveyed by the AMA. Overall, these developments paint a complex picture of scientific innovation intersecting with regulatory evolution and strategic industry adaptations aimed at enhancing patient outcomes while navigating economic pressures. As the industry evolves, stakeholders must remain vigilant and adaptable to seize opportunities and address challenges effectively.Support the show

Cheaper obesity medicines could unlock broader demand, while supply-chain bottlenecks and premium-drug innovation may also shape how the market evolves. Our analysts Terence Flynn and Thibault Boutherin break down the investor implications.Read more insights from Morgan Stanley.----- Transcript -----Terence Flynn: Welcome to Thoughts on the Market. I'm Terence Flynn, Morgan Stanley's U.S. Pharma and Biotech Analyst. Thibault Boutherin: And I'm Thibault Boutherin, Morgan Stanley's Europe Pharmaceuticals Analyst. Terence Flynn: Today, how cheaper GLP-1 obesity medicines could reshape access, pricing, and supply chains; and what the first generic markets may signal for Europe and the U.S. It's Monday, July 13th at 10am in New York. Thibault Boutherin: And it's 3 pm in London. Terence Flynn: Around one billion people live with obesity worldwide, including over a 100 million in the U.S. Right now, the introduction of the first lower cost generics of semaglutide, a GLP-1 medicine, in some international markets, could have consequences on affordability and demand. Thibault, what are the first countries seeing the introduction of sema generics? What are the current dynamics, and why should global investors pay attention? Thibault Boutherin: Sure. So, so far generics are being introduced this year in three countries: in India, Canada and Brazil. And if we look at India, this is the first market where the generics are being introduced. The patent for semaglutide expired in March 2026, and 13 companies have launched 26 generics across different formulations: autoinjectors, vials, and pills, which price is lower than the branded drug. And because the India market was quite under-penetrated for GLP-1, we are seeing affordability driving volume expansion. In Canada, two generics have been launched so far. Four other generics are waiting for approval, and more are being filed. And finally, in Brazil, one generic was approved last month, and we are expecting these generics to be launched in Brazil in July. And 17 other generics are in different stage of regulatory review in Brazil, and we would expect more to enter the market by the end of this year. And the reason why we focus on these markets is because we believe they could provide a blueprint for what could happen later in the U.S. and in Europe; in particular for Canada, which shares some characteristics with Europe and the U.S. And the patent for semaglutide will expire in Europe in 2031 and in the U.S. from 2032. Terence Flynn: Great. Maybe on the India front, I know that's at the leading edge. What happened with patient demand when price came down? Thibault Boutherin: Sure. So, what we saw in India is a surge in volume when generics were launched, and the volume in April 2026 were already six times higher than the volume in February. And that expansion has been driven mostly by these generics launch, which captured 80 percent of semaglutide volume in April. And our India team expect that the GLP-1 market in India will actually expand in value from $125 million in [20]25 to more than $1 billion by 2030, despite lower prices as we see better, you know, greater volume and greater adoption of GLP-1s in India. Terence Flynn: The other thing, you know, you and I have discussed is the supply chain, and one of the questions is the ability of some of the generic manufacturers to scale semaglutide. So, maybe talk to us about the current capabilities. And could we see bottlenecks in the supply chain formation here? Thibault Boutherin: Yeah, sure. So, there are three key elements to watch on the supply chain. The first is the active pharmaceutical ingredient or API, and that's the semaglutide molecule itself. The second element is the device and the device components, and the third element is the fill and finish, which is basically putting all of these things together. On the API side, so semaglutide molecule, we believe there will be no bottleneck in supplying for generics as we see a handful of large Chinese companies, out of China, building multi-ton capacity for semaglutide. So, we believe there will be no shortage of API to supply the generic supply chain for injectables. On the device, these are the same device companies that are supplying the branded version of semaglutide, and other GLP-1s for the device that are also supplying the generic makers. And we are seeing meaningful investments being made, so we don't believe there will be a bottleneck here. Where we could see a bottleneck emerging is on the fill and finish side. Fill and finish requires highly controlled clean room space to minimize contamination. It requires regulatory approval, and it takes up to three years to build fill and finish capacity. And so, that's where if there is not more investment being made over the next few years, there could potentially [be] a bottleneck emerging for the generic companies. Terence, while semaglutide generics will definitely represent a challenge for the existing branded version of this GLP-1, there are some insights in these emerging dynamics that suggest that tirzepatide, the other GLP-1, could be less at risk. Can you touch a bit on some of these dynamics? Terence Flynn: Absolutely. So, just to remind listeners that semaglutide targets a pathway called GLP-1. Tirzepatide actually targets two pathways. The first is GLP-1, and the second is GIP. And there are some data comparing these molecules, both in Type 2 diabetes and obesity. And tirzepatide gives not only better efficacy but also improved tolerability. And so, what you're seeing in some of the ex-U.S. markets is segmentation, where there are some consumers that are willing to pay a premium price for tirzepatide. Our team in Brazil has done a lot of work on this front looking at this dynamic and, you know, we expect that to play out in many geographies. So, despite the entry of lower-cost generic versions, we think you will still see segmentation of the market between differentiated brand and the lower-cost generics. And that as a result, you will continue to see branded growth.In the U.S. right now, market share is about 60 percent in favor of tirzepatide. And so again, you're seeing a differentiation between these two molecules. Thibault Boutherin: And beyond the introduction of generics GLP-1s, there are other dynamics in the industry that are driving this market. And the introduction of oral drugs this year has been a big topic. Terence, what are your views on the role that orals could play on the market? Terence Flynn: Yes, as a lot of people are probably aware, the many of the existing GLP-1 medicines are injectable. And so those are delivered once a week with a needle. But there are now additional oral options of these GLP-1 medicines. They started off first for Type 2 diabetes, but they have now broadened into obesity as well, following some recent FDA approvals. And what we're seeing is that the introduction in the U.S. so far is expanding the market. So, the majority of people that are taking the oral versions of these medicines are new users to GLP-1s. So again, you're getting market expansion. When you think about the orals as well, one of the other questions is capacity. I know, Thibault, you were talking about the supply chain. There are similar questions for these oral medicines because not all of the oral medicines are the same. Some are easier to manufacture than others, and as a result, that's another variable to consider. So, some of these are what's called peptide-based orals, and some of these are non-peptide-based orals. And the non-peptide-based orals are much easier to scale, for a larger global market. And so that's definitely another variable that we're monitoring and that I think investors need to consider. Thibault Boutherin: And beyond the pill versions of these GLP-1s, we are seeing more innovation in the drug pipeline of the industry, which could be a key driver of differentiation against the competition from the generics. So, what are we seeing emerging today from diabetes and obesity pipelines, which could be exciting for the future of the category? Terence Flynn: So, as we see time and time again in pharmaceutical markets, the key players continue to innovate to try to improve profiles of the existing medications. So, there are, you know, kind of two areas. One would be efficacy; another would be safety tolerability. And so, there are a number of players that are working first to develop longer acting medication. So, as I mentioned, the existing injectable drugs are dosed once weekly. But there are a number of companies that are working to develop potentially monthly or less frequent injections. So, that's one area that we're monitoring closely. And then the second, and again, this plays into what I discussed on tirzepatide, is additional pathways that are involved here in diabetes and obesity, and a number of players are working to target additional pathways beyond GLP-1 and GIP. And so, some of the leading pathways that are being studied are something called amylin and glucagon, and there are a number of medications that are in the late-stage pipeline that are coming along, which have some pretty interesting data. And so that's another area that we're watching. And again, the goal there would be to either improve efficacy and/or improve tolerability versus the existing medications. Thibault Boutherin: Great. And maybe we can also take this opportunity to talk about some of the short-term drivers in the market that are not facing generic today, like the U.S. So, what could be, you know, the key drivers for growth of GLP-1s and the overall obesity and diabetes category over the next five years? Terence Flynn: Yeah, obviously the key one is seeing additional uptake of these medicines. I think right now we estimate, again, obesity in particular, there's about low double-digit percent uptake. And so obviously seeing increasing uptake of these medicines. The orals, as I mentioned, are already driving market expansion. And then the third is access. So obviously in any market, that's very important. In the U.S., I think about 50 percent of employers cover these medications right now. We expect that to increase in the years ahead as the data continues to build. But then this year starting very shortly, the patients in the Medicare program in the U.S., so those people over the age of 65, will be able to access these medicines for $50 per month. And so, we think that is another driver of growth – is this will broaden access to about an additional 18 million people, starting this summer. So, the next phase of the diabesity market comes down to execution, lower cost and scaled supply in the mass market, and innovation and differentiation to compete in the premium segment. Thibault, thanks so much for taking the time to talk. Thibault Boutherin: Great speaking with you, Terence. Terence Flynn: And thanks for listening. If you enjoy Thoughts on the Market, please leave us a review wherever you listen and share the podcast with a friend or colleague today.

Over the last decade, the number of drug candidates entering development has doubled, yet the number of successful drug approvals remains flat at ~50 per year.This week, we sit down with Formation Bio founder and CEO Ben Liu. His company has raised more than $600 million to build what he hopes will become the first new enduring pharmaceutical company in decades, powered by AI. Ben explains why he believes clinical development, not drug discovery, is becoming the industry's biggest bottleneck, and how AI could fundamentally change the economics of bringing new medicines to patients.We cover:Why there hasn't there been a big pharma company created since the 1980sWhich drug categories Ben believes could become the next GLP-1s and reshape healthcareWhy Formation Bio chose to become a pharmaceutical company instead of selling softwareThe real bottleneck in bringing medicines to patientsBen's roadmap for how AI will transform drug development over the next 10 to 20 yearsAbout our guest:Ben Liu is the co-founder and CEO of Formation Bio. He received his DPhil at Oxford as a Rhodes Scholar, leveraging machine-learning, AI, and big-data to develop diagnostics and therapeutics for Parkinson's and Alzheimer's disease. During his graduate work, he observed the way clinical trials bottlenecked the development of new treatments for patients, compelling him to start Formation Bio.Before Formation Bio, Ben graduated from Yale where he was awarded the college's highest honor at graduation and received his MPhil with distinction in Computational Biology from the Department of Applied Mathematics and Theoretical Physics at Cambridge as a Paul Mellon Fellow. Ben also serves as an Advisor to Harvard Business School's MS/MBA Program in Biotechnology.—

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative updates and strategic shifts within the industry, reflecting both remarkable progress and inherent challenges. Sanofi's recent achievement marks a significant milestone in oncology with the FDA approval of Sarclisa Escena (isatuximab) as the first on-body injector for multiple myeloma treatment. This monoclonal antibody, targeting CD38, offers a novel subcutaneous delivery method, simplifying administration and potentially enhancing patient compliance by reducing the need for frequent clinic visits. This aligns with the industry's ongoing shift towards patient-friendly drug delivery systems, emphasizing convenience without compromising efficacy. In another promising development, GSK and Hansoh Pharmaceutical have reported positive results from their Phase 3 trial evaluating risvutatug rezetecan for small cell lung cancer. This antibody-drug conjugate, targeting B7-H3, has shown potential when combined with chemotherapy to extend patient survival. Given the aggressive nature of small cell lung cancer and limited treatment options, these findings underscore the potential of targeted therapies to improve clinical outcomes significantly. Forte Biosciences' FB102 also takes a spotlight in clinical advancements. In its Phase 1b trial for vitiligo, FB102 demonstrated a 45.8% placebo-adjusted benefit. This monoclonal antibody works by modulating immune responses through the IL-15 pathway via CD122, offering new hope for patients with this challenging autoimmune condition. On the regulatory front, ARPA-H's commitment of up to $160 million towards developing personalized genetic medicines for rare diseases is noteworthy. This investment is set to accelerate innovations in gene therapy and personalized medicine platforms. Such advancements promise to revolutionize pediatric care and extend beyond by tailoring treatments to individual genetic profiles, enhancing efficacy while minimizing adverse effects. Strategic collaborations continue to reshape the industry landscape. Rani Therapeutics' partnership with PegBio aims at advancing oral delivery systems for obesity and metabolic diseases. Similarly, Simcere Pharmaceutical's collaboration with Schrödinger leverages AI-driven drug discovery efforts. These alliances highlight an increased reliance on computational platforms to streamline therapeutic development processes. From a financial perspective, Mesoblast Limited reports substantial revenue from its cell therapy product Ryoncil, signaling strong commercial viability for cell-based treatments targeting rare diseases. Additionally, Cue Biopharma's successful $50 million fundraising underscores investor confidence in advancing therapies for immunological disorders. However, not all news is positive. Roche has decided to halt two programs targeting Huntington's disease due to inadequate efficacy and safety concerns. This decision reflects the complexities involved in developing effective treatments for neurological disorders—a field fraught with scientific challenges yet rich with potential rewards. In market dynamics, McKinsey's report advocates for a structural redesign of biopharmaceutical R&D to fully leverage AI's capabilities. This recommendation resonates with current industry trends focusing on strategic innovation to maximize efficiency and discovery potential. The FDA's third rejection of Hengrui Pharma and Elevar Therapeutics' combination therapy for liver cancer underscores the rigorous scrutiny such treatments face despite their promise in addressing complex cancers. In contrast, BioNTech's preparation to launch its HER2 antibody-drug conjugate (ADC) signifies its strategic pivot back towards oncology after mRNA vaccine successes. Bayer's decision to sell a minority stake in its contraceptives business demonstrates how companies are strategically realigning portfolios to focus on core areas while securing funding for innovation. This move reflects broader trends within pharma as companies navigate financial landscapes to support long-term research goals. Amid these developments, regulatory environments continue evolving. NICE's stance against future Lumakras reimbursement in the UK highlights ongoing challenges in balancing cost-effectiveness with access to innovative therapies. Meanwhile, ARPA-H's significant funding allocation signals robust governmental support for advancing precision medicine within genetic therapies. In conclusion, today's updates reveal an industry characterized by a relentless pursuit of innovation amidst complex regulatory landscapes. As companies navigate these dynamics through strategic collaborations and scientific breakthroughs, their efforts hold promise for enhancing patient care across diverse therapeutic areas globally. Stay tuned as we continue to track these exciting developments shaping the future of pharmaceuticals and biotechnology. Thank you for tuning into Pharma Daily—your go-to source for up-to-date insights from the world of pharmaceuticals and biotechnology.Support the show

Ryan Root, a former underground steroid kingpin, shares how he built a multi-million-dollar black-market empire, lost everything after one critical mistake, and ultimately rebuilt his life through a legitimate hormone therapy business.⁣ ⁣ Ryan's links - ⁣ https://goh4m.com/⁣ https://www.youtube.com/@GO_H4M/featured⁣ https://www.instagram.com/go_h4m/⁣ ⁣ Do you want to be a guest? Fill out the form https://www.insidetruecrimepodcast.com/apply-to-be-a-guest⁣ ⁣ Get 10% sitewide for a limited time. Just visit https://GhostBed.com/cox and use code COX at checkout. ⁣ ⁣ Shop my merch: https://www.etsy.com/shop/MatthewCoxCollection⁣ ⁣ Send me an email here: insidetruecrime@gmail.com⁣ ⁣ Do you extra clips and behind the scenes content?⁣ Subscribe to my Patreon: https://patreon.com/InsideTrueCrime ⁣ ⁣ Check out my Dark Docs YouTube channel here -⁣ https://www.youtube.com/@DarkDocsMatthewCox⁣ ⁣ Follow me on all socials!⁣ Instagram: https://www.instagram.com/insidetruecrime/⁣ TikTok: https://www.tiktok.com/@matthewcoxtruecrime⁣ ⁣ ⁣ Do you want a custom painting done by me? Check out my Etsy Store: https://www.etsy.com/shop/coxpopart⁣ ⁣ Listen to my True Crime Podcasts anywhere: https://anchor.fm/mattcox ⁣ ⁣ Check out my true crime books! ⁣ Shark in the Housing Pool: https://www.amazon.com/dp/B0851KBYCF⁣ Bent: https://www.amazon.com/dp/B0BV4GC7TM⁣ It's Insanity: https://www.amazon.com/dp/B08KFYXKK8⁣ Devil Exposed: https://www.amazon.com/dp/B08TH1WT5G⁣ Devil Exposed (The Abridgment): https://www.amazon.com/dp/1070682438⁣ The Program: https://www.amazon.com/dp/B0858W4G3K⁣ Bailout: https://www.barnesandnoble.com/w/bailout-matthew-cox/1142275402⁣ Dude, Where's My Hand-Grenade?: https://www.amazon.com/dp/B0BXNFHBDF/ref=tmm_pap_swatch_0?_encoding=UTF8&qid=1678623676&sr=1-1⁣ ⁣ Checkout my disturbingly twisted satiric novel!⁣ Stranger Danger: https://www.amazon.com/dp/B0BSWQP3WX⁣ ⁣ If you would like to support me directly, I accept donations here:⁣ Paypal: https://www.paypal.me/MattCox69⁣ Cashapp: $coxcon69⁣ ⁣ Chapters: ⁣ 01:40 - Discovering Testosterone's Impact⁣ 07:20 - Scaling the Black Market Operation⁣ 16:44 - Scaling, operations, and risks ️⁣ 27:50 - Making product and supply issues⁣ 39:41 - Shipment leak, DEA raid, and legal fallout⁣ 45:09 - Abduction and Interrogation Talk⁣ 51:30 - Federal Raid, Arrest, and Legal Fallout⁣ 1:00:12 - Prison Legal System Failures⁣ 1:08:31 - Business After Prison & HRT Clinic Success⁣ 1:15:15 - Testosterone benefits & medical stigma⁣ 1:17:45 - Neurotransmitters, mood, and hormone therapy ️⁣ 1:22:47 - Pharma, FDA, medical education, and industry influence ️⁣ 1:30:16 - Marketing & Simple Dosing⁣ 1:31:08 - Testosterone Protocols & Side Effects⁣ 1:45:19 - Pharmaceutical Influence & Patents⁣ 1:47:22 - Faulty Testosterone Studies & FDA Response ️⁣ 1:58:19 - Steroid Scare, Legislation & the War on Drugs ️⁣ 2:00:22 - Steroid Stigma and Comparative Deaths⁣ 2:02:24 - Steroids: Risks, Therapeutic vs Abusive, and Bodybuilding Data ️‍️⁣ 2:07:58 - Sugar Industry Fraud, Addiction, and Public Health Impact⁣ 2:15:27 - Prison for Selling Testosterone⁣ 2:16:00 - Government Failure on Endocrine Disruptors & Sugar ️⁣ 2:21:16 - Education, Treatment, and TRT Promotion Learn more about your ad choices. Visit megaphone.fm/adchoices

Live July 11, 2026 | Yaron Brook Show(Season 12, Episode 121)Commenting on Dr. Mike Israetel -- Capitalism, Pharma, Drugs & FDA | Yaron Brook ShowIs profit immoral—or is it the greatest force for human progress ever discovered?From World Cup fever and elite athletic performance to pharmaceutical innovation, patents, healthcare freedom, altruism, religion, and the philosophy behind capitalism, Yaron Brook takes on some of today's biggest intellectual controversies.Why do so many people resent profit? Why do we praise scientists while ignoring the entrepreneurs who make innovation possible? Should individuals—not governments—decide what medical risks they're willing to take? And why do ideas like altruism and collectivism continue to dominate modern culture?The discussion concludes with an outstanding live Q&A covering guilt and altruism, truth and rationality, aging and end-of-life ethics, Adam Smith on monopolies, radical Islam and the political spectrum, sunscreen myths, religion and freedom, and Richard Hanania's Kakistocracy.Whether you're interested in economics, philosophy, politics, healthcare, entrepreneurship, or Objectivism, this episode offers a perspective you won't hear anywhere else.Main Topics:00:00 Introduction & World Cup excitement02:13 What soccer teaches about virtue and excellence09:32 Why elite athletes deserve our admiration11:06 Enjoying sports without making them your life13:02 Bodybuilding, fitness, and Michael Israetel15:21 Michael Israetel's intellectual journey19:12 Why profit benefits everyone22:45 The myth of "excess profits" and collectivism30:21 Ambition, culture, and economic productivity32:25 Money vs. intrinsic motivation35:10 Property rights, freedom, and capitalism37:44 Pharmaceutical profits drive innovation40:28 Did Jonas Salk reject patents?43:21 Why patents matter47:10 Altruism versus self-interest in science49:02 Why businessmen are innovators too50:30 Passion and financial incentives54:00 The myth of sacrificing for society57:03 How profit improves everyone's lives1:00:37 Incentives, trade, and globalization1:03:17 Why FDA regulation slows innovation1:05:25 Should patients decide their own medical risks?1:10:09 Healthcare: individualism vs. collectivism1:13:14 Patient-doctor decision making1:14:13 Fighting today's anti-science movement1:15:58 London Documentary fundraising update1:17:17 The truth about ancient life expectancy1:19:27 Upcoming Phoenix courses1:21:24 Ayn Rand Institute conference in Austin1:23:06 Alex Epstein, AI, and the future of energyLive Audience Questions1:25:34 Is altruism really driven by guilt—and why do facts fail to persuade true believers?1:28:45 How can people go through life without treating truth as an objective standard?1:30:06 What is the rational approach to aging, dependence, and end-of-life care?1:32:02 Why classify radical Islamists with the political left rather than the right?1:33:44 Did Adam Smith actually support government regulation to prevent monopolies?1:35:02 A practical question: Should you wear sunscreen every day—even when it's cloudy?1:37:26 Which poses the greater threat to individual freedom today—Catholicism or Islam?1:43:54 Richard Hanania's Kakistocracy: Is it worth reading despite its philosophical inconsistencies?Subscribe for daily analysis on economics, politics, philosophy, technology, investing, and current events.#pharmaceutical #Capitalism #Objectivism #Trump #Economics #Profit #FreeMarkets #Innovation #Entrepreneurship #Healthcare #worldcup The Yaron Brook Show is Sponsored by[The Ayn Rand Institute](https://www.aynrand.org/starthere)[Energy Talking Points, featuring AlexAI, by Alex Epstein](https://alexepstein.substack.com/)[Express VPN](https://www.expressvpn.com/yaron)[Hendershott Wealth Management](https://www.youtube.com/watch?v=X4lfC...) &(https://hendershottwealth.com/ybs/)[Michael Williams & The Defenders of Capitalism Project](https://www.DefendersOfCapitalism.com)[Support the Show]( / yaronbrookshow )[Sponsor the Show](askyaron@yaronbrookshow.com/)[One-time donation](https://bit.ly/2RZOyJJ)Join the [Yaron Brook Show YouTube channel]( / @yaronbrook )Like what you hear? Like, share, and subscribe to stay updated on new videos and help promote the [Yaron Brook Show](https://bit.ly/3ztPxTx)Continue the discussion by following Yaron on [Twitter](https://bit.ly/3iMGl6z) and [Facebook](https://bit.ly/3vvWDDC )Want to learn more about Ayn Rand and Objectivism? Visit the [Ayn Rand Institute](https://bit.ly/35qoEC3)Become a supporter of this podcast: https://www.spreaker.com/podcast/yaron-brook-show--3276901/support.Yaron is the executive chairman of the Ayn Rand Institute and a world class speaker. He is the coauthor of the national best-seller Free Market Revolution: How Ayn Rand's Ideas Can End Big Government, Equal is Unfair: America's Misguided Fight Against Income Inequality and In Pursuit of Wealth: The Moral Case for Finance. He speaks around the world on a variety of topics including the morality of capitalism, Ayn Rand and her philosophy, finance and economics, and the value of inequality.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Evren Ozkaya is the Founder & CEO of Supply Chain Wizard and SCW.AI.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Evren, covering:   The job offer that pulled him away from the McKinsey fast track and into the pharma industry Getting hands on experience at Sandoz, delivering real impact before spotting the opportunity to found his own business The moment that triggered the shift from consulting to technology, and the rapid build out of a software platform The decision to spin out the Digital Factory into a standalone company and raise $10m in Series A funding The importance of simplicity and creating a single source of truth on the factory floor Why the industry must move towards interconnected, systems thinking rather than isolated point to point solutions Why strong networks remain a hidden but powerful advantage in the life sciences sector   Evren Ozkaya, Ph.D. is the Founder & CEO of Supply Chain Wizard (a management consulting firm) and SCW.AI (a technology platform company), helping Pharma manufacturers establish and execute cost-effective and scalable digital transformation programs across manufacturing and supply chain domains by leveraging the state-of-the-art technology.   As a former management consultant at McKinsey & Company and a supply chain executive at Sandoz/Novartis, Dr. Ozkaya led various business transformation programs in over 100 companies in industries such as pharmaceuticals, consumer goods, industrial, logistics and private equity.   Evren Ozkaya received his Ph.D. in Industrial and Systems Engineering from Georgia Institute of Technology with his award-winning thesis on Demand Management in Global Supply Chains. Dr. Ozkaya currently serves as the Chair of the Advisory Board at the School of Industrial and Systems Engineering at Georgia Tech, besides his other advisory board roles at Rutgers Business School and Seton Hall University.   Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and challenges shaping the landscape of these dynamic sectors. Starting with Ipsen's Dysport, which has made notable strides in its Phase 3 trials for migraine prevention. The trials covered both episodic and chronic conditions, marking a first in the neurotoxin market. Dysport's success positions it as a formidable competitor to AbbVie's Botox, expanding therapeutic options for individuals battling migraine disorders. This achievement showcases the potential efficacy of botulinum toxin-based therapies in neurology and pain management, offering promising new avenues for patient care. In regulatory news, Boehringer Ingelheim has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for Jascayd, a small molecule PDE4B inhibitor with antifibrotic properties. This approval marks a significant milestone in the treatment of idiopathic and progressive pulmonary fibrosis. Jascayd's addition to the therapeutic arsenal offers new hope for managing this debilitating condition, emphasizing the ongoing efforts to improve patient outcomes through innovative treatments. The arena of business development sees HanChorBio partnering with InxMed to advance oncology research. By combining HCB101 with FAK inhibitors and FAP-targeted ADCs, this collaboration aims to leverage antibody and small molecule drug discovery techniques. The goal is to develop innovative cancer treatments that could redefine therapeutic approaches in oncology. Keenova Therapeutics has also reported success with Xiaflex for plantar fibromatosis. This enzyme injection therapy offers a novel approach by targeting collagen, thus providing an innovative solution for musculoskeletal conditions. Similarly, Fate Therapeutics' FT819, an off-the-shelf CAR-T therapy, has shown early promise in tackling treatment-resistant systemic sclerosis, underscoring the potential of cell therapies beyond oncology. Meanwhile, MindRank's successful Series B funding round of $52 million highlights the growing role of AI platforms in drug discovery. The funding will propel its AI-discovered oral GLP-1 obesity pill into Phase III trials, exemplifying how technology-driven solutions are gaining traction in addressing metabolic diseases like obesity. On the regulatory front, Saol Therapeutics has resubmitted SL1009 (DCA) to the FDA for pyruvate dehydrogenase complex deficiency. This submission underscores ongoing efforts to address rare metabolic disorders using small molecule therapies. Additionally, Sanofi's concessions to the EU regarding flu vaccine marketing illustrate the complexities of competitive dynamics and regulatory scrutiny within the vaccine market. However, not all developments are favorable. AstraZeneca and Ionis Pharmaceuticals faced a setback as their drug Wainua failed its Phase 3 trial for transthyretin-mediated amyloid cardiomyopathy. This outcome highlights the challenges inherent in developing effective treatments for complex cardiovascular conditions. Meanwhile, regulatory processes remain contentious as the FDA pauses its release of complete response letters amid debates over proprietary information disclosures. In another noteworthy development, GSK has terminated its $2.2 billion collaboration with Alector after underwhelming results from Alzheimer's drug trials. This decision highlights both financial implications and strategic shifts as companies reassess risk tolerance in neurodegenerative disease research. Conversely, Roche's success with its KRAS G12C inhibitor divarasib in Phase 3 lung cancer trials underscores the promise of precision medicine. Divarasib outperformed competitors Amgen's Lumakras and Bristol Myers Squibb's Krazati, positioning Roche to potentially redefine standards of care based on genetic profiles. In a move reflecting industry trends towards collaboration and innovation risk-sharing models, AstraZeneca has partnered with Sino Biopharmaceutical on respiratory disease research. This strategic alliance represents a substantial investment aimed at expanding AstraZeneca's pipeline in respiratory therapeutics. Lastly, amidst these developments, psychedelic drugs are experiencing a renaissance in psychiatric care. Companies like Compass Pathways are pioneering clinical validation for their use in treating depression, signaling a potential paradigm shift from traditional SSRIs to newer therapeutic classes pending safety and efficacy data. Overall, these stories illustrate a dynamic interplay of scientific progress and regulatory navigation within the pharmaceutical and biotech sectors. While challenges persist—particularly in neurodegenerative disease treatment—the breakthroughs in oncology and metabolic disorder therapeutics offer hopeful prospects for improving patient care. As these industries continue evolving, integrating advanced technologies such as AI will likely play a pivotal role in shaping future therapeutic landscapes.Support the show

By the time the paper hit version 71, Dr. Nirosha Murugan had already done the hard part. The data were real. The experiment had worked. A team of researchers had used a wearable bioreactor to trigger limb regeneration in frogs, a result with obvious implications for regenerative medicine. But the science still wasn't getting over the line. The problem wasn't the work. It was the translation.On this episode of Standard Deviation, host Oliver Bogler talks with Dr. Nirosha Murugan, a biophysicist and Tier II Canada Research Chair in Tissue Biophysics at Wilfrid Laurier University, about what happens when a scientist working at the edges of quantum biology, bioelectricity, and tissue regeneration runs headfirst into the unwritten rules of academic publishing. Murugan's research asks biologists to think beyond molecules and chemistry alone, and to consider the physical signals, electromagnetic fields, and invisible forces that shape development and healing. It is ambitious science. It is also exactly the kind of work that can make gatekeepers nervous.Bogler follows Murugan through the less glamorous part of discovery: the hidden curriculum of getting a paper published, securing scientific credibility, and learning that data do not simply “speak for themselves.” Murugan describes how jargon buried the pitch of her own work, how a lack of editorial support left her at a disadvantage, and how the JEDI program at the Life Science Editors Foundation paired her with a former journal editor who taught her how to structure a manuscript, write a cover letter, and survive peer review.The result was publication in Science Advances, but the larger story is about power. Who gets taught the rules of biomedical research. Who has access to grant writers, editors, and institutional polish. Who is left to brute-force their way through the maze. And how one scientist, having finally found the map, now makes sure her own trainees do not have to learn it the hard way.RELATED LINKSDr. Nirosha Murugan⁠Wilfrid Laurier University⁠Life Science Editors Foundation⁠JEDI Program⁠Science Advances paper on limb regeneration⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Pharma portfolios can create powerful opportunities, but without clear positioning, brands can end up competing with each other. In this episode, Lumanity's Jakub Kaczor, VP, Strategy Consulting, and Peter Smith, SVP, Strategy Consulting, discuss the complexities of portfolio positioning in the pharmaceutical industry. The guests explain that while a focused R&D strategy drives commercial growth and sustained innovation, it also creates a paradox where a company's own assets can end up competing against each other in the same disease area. To mitigate internal rivalry and maximize commercial potential, they advise companies to begin co-positioning early and follow a structured planning process, grounded in market reality. Ultimately, achieving portfolio success requires overcoming brand egos through a collaborative mindset, establishing clear governance under a dedicated portfolio owner, and designing strategies that anticipate the future competitive landscape. Tune in to learn how pharma teams can reduce internal competition, improve customer clarity, and build stronger portfolios that serve both patients and commercial goals! Resources: Connect with and follow Jakub Kaczor on LinkedIn. Connect with and follow Peter Smith on LinkedIn. Follow Lumanity on LinkedIn and explore their website! Learn more about this series we're doing with Lumanity here:  https://lumanity.com/commercialization-podcasts/

The Pharma boys review the USMNT's disappointing result, talk general World Cup vibes and revisit their predictions. With MLS returning next week, some Nashville SC discussion was needed as well!

At a company as large and complex as Pfizer, investor relations isn't just about answering questions. It's about architecting a story that works for a PhD and a generalist in the same room. In this episode of Winning IR, Mark Fasken speaks with Francesca DeMartino, Chief Investor Relations Officer at Pfizer, about what it takes to run a world-class IR program inside one of the most scientifically complex, brand-recognizable, and closely scrutinized companies on the planet. Drawing on over 25 years of experience across pharma, med tech, investment banking, and corporate communications, Francesca shares how she builds her bench, controls the narrative, and earns her seat at the table.Listen to the full episode to learn more about:Why pharma IR is unlike any other sector and what IROs everywhere can learn from itHow to tailor your story for generalist and specialist investors, sometimes in the very same meetingWhy Francesca abandoned traditional Q&A documents in favor of message maps and why you should tooHow to build an IR team that is truly fit for purpose, and what skill sets matter mostThe three pillars of a great IR program: storytelling, consensus management, and targeting — and how to master all threeWinning IR is brought to you by Irwin. For more winning ideas, subscribe to Winning IR wherever you get your podcasts.For more information, visit getirwin.com/winning-ir

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping our industry, starting with a significant regulatory milestone. Vera Therapeutics recently achieved FDA accelerated approval for Trutakna, a groundbreaking treatment for IgA nephropathy. This approval not only provides new hope for patients suffering from this chronic kidney disease but also highlights the innovative approach targeting APRIL and BAFF pathways, crucial in immune system regulation. The drug's accelerated approval is particularly noteworthy as it offers earlier access to promising therapies while further trials solidify its benefits. This positions Vera Therapeutics against industry giants like Novartis and Otsuka in nephrology therapeutics, highlighting the competitive landscape within this sector. The FDA's expedited pathways are increasingly facilitating quicker access to life-saving drugs, aligning regulatory processes with scientific advancements to address unmet medical needs. The spotlight on fusion proteins in tackling autoimmune and renal disorders could signal a broader trend in therapeutic development. In parallel, AstraZeneca has made waves by entering into a major licensing agreement with Sino Biopharmaceutical for their COPD candidate TQC3721. This $1.9 billion deal, with a $200 million upfront payment, exemplifies how global collaborations are becoming pivotal in expanding market reach. By focusing on respiratory diseases, AstraZeneca is strategically positioning itself to enhance treatment options for COPD patients worldwide, reflecting an industry-wide movement towards leveraging regional expertise in drug commercialization. Meanwhile, Evonik's $100 million investment in an Indiana API manufacturing plant marks a strategic effort to bolster domestic production capacities post-pandemic. This investment underscores the rising demand for Contract Development and Manufacturing Organization (CDMO) services, emphasizing supply chain resilience—an increasingly critical factor as biotech firms seek reliable production partners. On the clinical trial front, Satellos Bioscience has reported promising Phase 1 data for SAT-3247, its Duchenne muscular dystrophy candidate. This AAK1 inhibitor demonstrates potential in promoting muscle regeneration, a development that could significantly alter treatment paradigms for this progressive neuromuscular disorder. If further trials confirm these findings, it could revolutionize therapeutic approaches for rare diseases. Financially, Leo Cancer Care's recent $65 million Series D funding is set to advance its upright radiotherapy treatment system. Such innovations aim to improve precision and outcomes in cancer therapy, at the intersection of technology and patient care. Similarly, MeiraGTx's securing of up to $400 million from Oberland Capital underlines ongoing confidence in gene therapies targeting rare ophthalmological conditions. Strategic maneuvers continue to reshape industry landscapes with mergers like that of Caidya and Simbec-Orion forming a global CRO platform aimed at enhancing research capabilities across oncology and rare diseases. Such consolidations reflect broader trends towards operational efficiencies and scaling research capabilities globally. Amidst these developments, quality control remains paramount as evidenced by Amgen's recall of its heart failure drug due to quality concerns. Such challenges reiterate the importance of stringent quality assurance throughout production processes in safeguarding patient safety. Vertex's acquisition of Crinetics for $10 billion marks another strategic expansion into "white space blockbuster opportunities," illustrating how M&A activity is driving companies to bolster pipelines and capitalize on emerging scientific advancements. These developments collectively underscore the dynamic nature of the pharmaceutical and biotech industries as they navigate complex regulatory landscapes, financial recalibrations, and scientific breakthroughs. As companies strive towards more effective and accessible treatments across various therapeutic areas, their ability to adapt to these challenges remains crucial in shaping the future of healthcare delivery. Thank you for tuning into Pharma Daily. Stay informed with us as we continue to bring you the latest insights from the world of pharmaceuticals and biotechnology.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that showcase the dynamic nature of this industry. In a landmark development, Vertex Pharmaceuticals has made headlines with its acquisition of Crinetics Pharmaceuticals for a staggering $10 billion. This move marks Vertex's strategic expansion into the endocrine disease sector, a significant shift from its traditional focus on cystic fibrosis. Crinetics' innovative approach to treating rare endocrine disorders will allow Vertex to address unmet needs in this area, highlighting a broader industry trend where mergers and acquisitions serve as key strategies for adapting to the evolving scientific landscape and patient demands. While Vertex makes bold moves, Kalohexis is preparing for a confidential initial public offering (IPO), focusing on treatments based on the melanocortin system for obesity and cancer cachexia. The melanocortin system is crucial in regulating energy homeostasis and inflammation, making it a promising target for therapeutic interventions. This development underscores the growing interest in peptide-based therapies and innovative scientific approaches to address complex metabolic disorders, further emphasizing the industry's shift towards tackling significant health challenges such as obesity. Clinical trials continue to be at the forefront of medical advancements. Compass Pathways has reported promising Phase III trial results for COMP360, its psilocybin-based therapy for treatment-resistant depression. These findings indicate a potential breakthrough in psychedelic therapy, offering new hope for patients who haven't benefited from existing antidepressant treatments. The exploration of psychedelics in mental health treatment represents a paradigm shift that could introduce novel therapeutic options and significantly impact patient care. Turning to regulatory news, AbbVie's Tepkinly (epcoritamab) has received European Commission approval for treating relapsed or refractory follicular lymphoma. This approval is based on robust Phase III data, underscoring the potential of bispecific antibodies as effective cancer therapies. Similarly, PharmaEssentia's Besremi (ropeginterferon alfa-2b) has obtained Health Canada approval for polycythemia vera treatment, highlighting the continued relevance of protein and interferon therapies in managing myeloproliferative neoplasms. In business development news, Novo Nordisk and Vivani Medical have partnered to develop an ultra-long-acting semaglutide implant for chronic weight management. This collaboration showcases advancements in drug delivery systems aimed at improving patient compliance and therapeutic outcomes. Meanwhile, Boehringer Ingelheim's licensing agreement with Prime Vector Technologies involves harnessing viral vectors for cancer vaccine development, emphasizing ongoing efforts to innovate within oncology. Despite these advancements, challenges persist within the industry. Notably, Bristol Myers Squibb's Krazati (adagrasib) failed its Phase III confirmatory trial in metastatic colorectal cancer with KRAS G12C mutations. This outcome highlights the complexities involved in developing targeted cancer therapies and underscores the need for continued innovation and exploration of combination treatments. The financial landscape also reflects strategic adjustments with Regeneron Pharmaceuticals reporting a $127 million charge impacting its earnings due to an in-process research and development expense. Additionally, Novartis is undergoing organizational restructuring with workforce reductions aimed at cost management within large pharmaceutical enterprises. On another front, China's recent approval of the world's first CAR-T therapy for solid tumors marks a significant leap forward from its traditional success in hematological malignancies. This development highlights the potential for CAR-T therapies to address complex challenges posed by solid tumors and could have profound implications for global cancer treatment paradigms. AstraZeneca's partnership with CSPC Pharmaceutical represents another strategic collaboration aimed at co-developing kidney disease drugs, reflecting Western pharmaceutical companies' efforts to leverage Chinese biotechnological capabilities. As companies navigate these complexities through strategic acquisitions, partnerships, and groundbreaking research, their ability to adapt will be crucial in shaping future patient care and therapeutic landscapes. The pharmaceutical and biotech industries remain at the forefront of scientific advancement, continually seeking solutions to complex medical needs while adapting to an ever-evolving global landscape.Support the show

Dr. Jess Peatross trained in conventional medicine and worked as a hospitalist before she started questioning why so many chronically ill patients kept getting worse inside the healthcare system she trusted. Her perspective carries weight because she spent years following every protocol exactly as taught before walking away from hospital medicine entirely.Raised in Huntington, West Virginia during the opioid crisis, she entered medicine believing the system existed to heal people. Instead, she found hospitals driven by billing codes, liability management, and pharmaceutical dependence while patients with chronic illness, autoimmune disease, mold exposure, and chronic pain cycled endlessly through appointments and prescriptions.Dr. Peatross explains what pushed her toward functional medicine, cannabis therapy, and prevention focused care after watching patients improve only after leaving conventional treatment pipelines behind. The conversation tackles physician burnout, chronic illness stigma, healthcare incentives, and the growing collapse of trust between patients and institutions.The discussion also moves into supplements, environmental toxins, ultra processed food, and the uncomfortable economics behind keeping people permanently sick but continuously billable. Dr. Peatross describes the professional backlash that comes with challenging medical orthodoxy while Matthew connects her experience to the broader erosion of public trust across American healthcare.Together they unpack what happens when patients stop believing the system can help them and start searching elsewhere for answers.RELATED LINKSDr. Jess PeatrossInstagramMarshall UniversityBrave New WeedFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Heather asks and helps answer “How do you create a point of view about your solution in a way that will talk to Salesforce about how it works together for that specific customer?” For ISVs so they can take a strong point of view about a specific customer vs. approaching with just questions. “It's easier to find this information than it's ever been. Don't be lazy and use the tools and you will have much better conversations.”This episode of How We Got There features a conversation with Heather Mason, Founder of ISV Accelerators. Heather brings their clients her knowledge forged by experiences at an ISV (Insight Squared) and Salesforce themselves, 5.5 years at each company. Her company works with “high potential” Salesforce partners to assist their GTM motions in the ecosystem - Salesforce, other ISVs, and SIs - so the ISV can help make it easier for the customer to buy the solution.We talked a bit about the challenges her team faced at Salesforce within her focus on the Pharma vertical, which had a strong publicly traded OEM of Salesforce in Veeva to contend/cooperate with and the new-normal of fewer people at Salesforce focused on ISVs. Partners need to adapt to how Salesforce is changing their selling motion, aligning to Salesforce AEs with modern better together messaging. The challenge is Salesforce is still figuring it (it being Agentforce) out too. Heather shares insights around traffic on the AppExchange listing by most common personas and what it means to ISVs through the lens of who buys their solution. At the level, the Salesforce sales team aligned to a specific account can be over 20 people but at the SMB level it might just be an AE and their RVP, who will be VERY hands on with the deal alongside their AE.We touch on big strategy but also tactics around things like when is the right moment to reach out to the Salesforce account team in an opportunity cycle. It all starts with you having a unique value to share and if you do, you should expect an 85% positive response rate. If you are lower than that, I would challenge you to harden your messaging.Heather loves to connect with people in the ecosystem and takes pride in making herself available to meeting new people. I learned a ton from my conversation with Heather and am grateful she is actively helping ISVs and OEMs in the ecosystem. Connect with Heather at the Arcadia leadership experience in Montana run by the Yarboroughs.This episode is brought to you by ISVApp. ISVapp the usage analytics platform built specifically for Salesforce ISV and OEM applications. ISVapp is your central toolbox for reducing churn, increasing renewals, uncovering upsell opportunities, and closing more deals. #salesforce #isv #gtm #salesforcepartners #appexchange

The framework of modern pharmaceutical manufacturing is evolving as new technologies, advanced therapeutic modalities, and more sophisticated process control reshape how medicines are developed. While biologics, peptides, and other emerging therapies continue to expand the industry's capabilities, advances in engineering, automation, and continuous manufacturing are also transforming small molecule manufacturing. These shifts are redefining the skills, technologies, and manufacturing strategies needed to deliver high-quality medicines more efficiently and reliably. In this episode of Off Script, we spoke with Thomas Roper, PhD, co-director of pharmaceutical engineering at Virginia Commonwealth University's Center for Pharmaceutical Engineering and Sciences and graduate program director for chemical and life science engineering, about how pharma manufacturing has evolved over the course of his career and where it's headed. Roper draws on decades of experience to discuss the significance of chemical engineering in small molecule manufacturing, the growing significance of quality by control, the promise and challenges of continuous manufacturing, and how emerging catalytic technologies and automation are advancing process development. He also shares why preparing the next generation of pharmaceutical scientists and engineers will be critical as traditional boundaries between small molecules, biologics, and emerging modalities continue to disappear.

Rachel Fox and Justin Nielsen walk through Monday's market action and discuss key stocks to watch in Stock Market Today. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The first quarter of 2026 has brought a wave of significant changes and advancements in the industry, marked by crucial regulatory updates, strategic acquisitions, and shifts in the competitive landscape. A pressing issue for many companies is the looming patent cliff for several branded biologics. This situation presents both challenges and opportunities for biosimilars in the U.S. market. The introduction of biosimilars for major products like AbbVie's Humira, Johnson & Johnson's Stelara, and Regeneron/Bayer's Eylea is shifting the narrative from slow adoption to a more competitive biosimilar market landscape. Vertex Pharmaceuticals has achieved a milestone with the FDA expanding the label for its gene therapy Casgevy, now approved for treating children as young as two with sickle cell disease or transfusion-dependent beta thalassemia. This expansion emphasizes the potential of gene therapies to revolutionize treatment options for younger patients suffering from these conditions. In a pivotal development, Novartis announced a significant acquisition of UK biotech Myricx. With an upfront payment of $1.1 billion and potential total value up to $1.5 billion, this acquisition is set to enhance Novartis' antibody-drug conjugate (ADC) pipeline by incorporating Myricx's novel payload technology and NMT inhibitor payloads. This move reflects Novartis' focus on precision oncology by improving ADC efficacy through targeting critical enzymatic pathways involved in tumorigenesis. Amgen faced a setback with a voluntary recall of approximately one million bottles of its heart medication Corlanor due to potential contamination, highlighting the critical importance of maintaining rigorous manufacturing quality control to ensure drug safety. The regulatory landscape continues to evolve, illustrated by Robert F. Kennedy Jr.'s Department of Health and Human Services revoking lingering COVID-19 emergency authorizations. This signals a transition towards post-pandemic normalcy and an evolving focus on pandemic preparedness frameworks. Sanofi's Genzyme unit in Ireland faced criticism after an FDA inspection linked to Altuviiio resulted in a Form 483 notice. This incident underscores ongoing challenges in maintaining compliance with stringent regulatory standards and emphasizes the importance of robust quality assurance mechanisms. Lonza is expanding its capacity for producing ADCs and enhancing its partnership with a large U.S. drugmaker, aligning with industry trends toward outsourcing complex biologics manufacturing amid growing demand for ADCs. Genentech is undergoing restructuring, resulting in 103 layoffs as part of a strategic rethink of its early development group. Despite these changes, Genentech entered a $490 million collaboration focused on breast cancer, demonstrating its commitment to innovation amid organizational shifts. AstraZeneca continued its collaborative efforts by signing a $1.7 billion kidney drug discovery pact with Chinese biotech CSPC Pharmaceutical. This partnership emphasizes AstraZeneca's strategy to leverage global collaborations to accelerate drug discovery and development efforts. Scribe Therapeutics filed for an Initial Public Offering (IPO) to advance its CRISPR-based gene editing technologies targeting cardiovascular diseases at a genetic level, highlighting an ongoing shift toward personalized medicine. Celea Therapeutics raised $180 million in venture funding to advance Deupirfenidone into late-stage clinical trials for Idiopathic Pulmonary Fibrosis (IPF), signaling confidence in its therapeutic potential amid ongoing investment trends targeting rare diseases. The Medicines and Healthcare products Regulatory Agency expanded approval for Novo Nordisk's Wegovy for Metabolic-Associated Steatohepatitis with moderate-to-advanced liver fibrosis. This expansion represents significant progress given MASH's rising prevalence and progression risks. BridgeBio's ATTRibute-CM study yielded promising results with Acoramidis offering kidney-protective benefits in transthyretin amyloidosis cardiomyopathy patients—a potential new approach managing this rare disease. Revolution Medicines reported encouraging data for its KRAS inhibitor Zoldonrasib in combination therapies targeting metastatic pancreatic ductal adenocarcinoma—offering new strategies against aggressive cancer types. Brii Bio's phase 2b trial results show promise for a combination therapy aimed at achieving a functional cure for chronic Hepatitis B Virus infection—offering hope for millions affected by this condition. Robust fundraising activities continue within biotech sectors as Monash University and Atisama Therapeutics secure funding from MRFF grants developing therapies targeting chronic lung diseases. Overall, these developments highlight dynamic transformations reshaping therapeutic landscapes through precision medicine approaches leveraging cutting-edge technologies promising improved patient care across various domains within pharmaceutical industries globally.Support the show

Our good friend, Reaper of Reaper Consultations, returns to the show with B.R this week to discuss his turn to natural medicine. The lads get into a general rejection of modernity, from Reaper's local involvement against Flock cameras, detoxing from social media, and getting free of doom and gloom headlines. Reaper later discusses how he's been growing and creating his own natural medicine, how his triumph over cancer lead him away from big Pharma, where listeners can get started with growing and making their own natural cures, and much more!Check out our Guest:Reaper - https://www.instagram.com/reaperconsultation/Check out our link tree for all of our stuff:⁠⁠⁠⁠⁠https://brand.page/theartandwarpodcast⁠⁠⁠⁠⁠Follow the lads on IG:     ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Nathan / Main Page: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/cbrnart/?hl=en⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠B.R: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/br.the.anarch⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Al: ⁠⁠https://www.instagram.com/freedom.visualizations/⁠⁠Phil: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/philmxengland/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

This interview is disseminated on behalf of Medicus Pharma Ltd.With Phase 2 studies moving forward across its clinical programs, Medicus Pharma (NASDAQ: MDCX) is also planning to evaluate the use of its SkinJect anti-skin cancer patch to combat Gorlin Syndrome, a rare genetic disorder, as well as Teverelix for the potential treatment of endometriosis.Executive Chairman and CEO Dr. Raza Bokhari shares more details about the company's FDA application to test SkinJect in Gorlin Syndrome patients, its genomics-enabled clinical trial in Abu Dhabi for Teverelix's use in endometriosis, and anticipated growth milestones, including potential strategic partnerships.Learn more about Medicus Pharma: https://medicuspharma.com/Watch the full YouTube interview here: https://youtu.be/v_ZhrQE2DFMAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia

Listener discretion is advised.

Send us Fan MailThe pharmaceutical industry encompasses a wide range of business models, making ERP selection a highly strategic decision that extends well beyond feature comparisons. Before evaluating the top pharmaceutical ERP systems in 2026, it is essential to understand the diversity of the market and the unique operational, regulatory, and supply chain requirements that different organizations face. This analysis examines pharmaceutical companies of all sizes, from emerging biotech firms and specialty manufacturers to large global enterprises, each with distinct needs related to compliance, quality management, traceability, production, and commercialization. As a result, selecting the right ERP platform requires careful alignment with an organization's business model, growth trajectory, and long-term operational strategy.In this episode, our host Sam Gupta discusses the top pharma ERP systems in 2026. He also discusses several variables that influence the rankings of these ERP systems. Finally, he shares the pros and cons of each ERP system.Video: https://www.youtube.com/watch?v=l0FOuPd2VMARead: https://www.elevatiq.com/post/top-pharma-erp-systems/Questions for Panelists?

The Big Unlock · Naomi Fried, PhD, Founder and CEO, PharmStars In this episode, Naomi Fried, PhD, Founder and CEO of PharmStars, shares how stronger collaboration between startups and pharmaceutical companies is accelerating healthcare innovation. Drawing on leadership roles at Biogen, Kaiser Permanente, Boston Children's Hospital, consulting work with large pharma companies, and collaboration across the digital health ecosystem, she explains why the most successful innovations are built around customer needs rather than technology alone. Naomi discusses how PharmStars helps digital health startups, including those developing AI-powered solutions, understand the pharmaceutical industry, refine their value proposition, and build lasting partnerships with global pharma companies. She highlights AI as one of the most exciting areas of innovation, with the potential to improve patient care, support clinicians, and create new opportunities for life sciences organizations. However, Naomi emphasizes that technology alone is never enough. Successful innovators listen more than they pitch, understand customer pain points, and build trusted relationships. Naomi also talks about the importance of clinician workflows, internal champions, and continuous product evolution. Whether leveraging AI, software, or medical devices, her message is clear: lasting innovation comes from solving meaningful problems, adapting to customer needs, and building partnerships that create real-world impact. Take a listen.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we dive into some significant advancements reshaping the industry. Starting with a breakthrough in gene therapy, researchers have announced promising results from a Phase 1 clinical trial targeting a rare genetic disorder known as Leber congenital amaurosis. This disorder causes childhood blindness due to mutations in the RPE65 gene. The investigational therapy involves delivering a functional copy of the gene directly to retinal cells using an adeno-associated virus vector, showing substantial improvements in visual function for participants. This development not only brings hope to those affected by this condition but also underscores the growing potential of gene editing technologies in addressing previously untreatable genetic disorders. While these are early-stage results, they contribute to a growing body of evidence that gene therapy can effectively target and treat specific genetic abnormalities. In regulatory news, the FDA has granted accelerated approval to a novel small-molecule drug for the treatment of metastatic triple-negative breast cancer. This drug acts as an inhibitor of a specific kinase involved in cancer cell proliferation and has shown statistically significant improvements in progression-free survival compared to existing therapies. Triple-negative breast cancer is particularly challenging to treat due to its aggressive nature and lack of hormone receptors that typically guide treatment decisions. The approval marks a critical step forward, offering a new therapeutic option for patients with limited alternatives. As this treatment enters broader clinical use, ongoing post-marketing studies will be crucial in confirming its long-term efficacy and safety profile. Meanwhile, in Europe, the European Medicines Agency has recommended approval for an innovative biologic targeting severe asthma. This monoclonal antibody works by selectively binding to and inhibiting a cytokine involved in the inflammatory cascade that triggers asthma symptoms. Clinical trials demonstrated significant reductions in asthma exacerbations and improved lung function among patients who were inadequately controlled on standard therapies. With asthma affecting millions globally, advancements like these are essential for improving quality of life and reducing healthcare burdens associated with poorly controlled respiratory conditions. Turning our attention to Alzheimer's research, scientists have reported encouraging findings from a late-phase clinical trial evaluating a novel anti-amyloid antibody. The trial results indicate that the drug successfully slowed cognitive decline in patients with early-stage Alzheimer's disease. This aligns with the amyloid hypothesis, which suggests that amyloid-beta plaque accumulation in the brain is a driving factor in Alzheimer's pathology. Although previous attempts targeting amyloid have met with limited success, this latest trial offers renewed optimism for potentially modifying disease progression rather than just managing symptoms. On the topic of industry trends, there's been a notable increase in strategic partnerships between major pharmaceutical companies and emerging biotech firms specializing in mRNA technology. Following the unprecedented success of mRNA vaccines during the COVID-19 pandemic, there is considerable interest in exploring mRNA platforms for treating a wide range of diseases beyond infectious ones, including cancer and rare genetic disorders. These collaborations aim to leverage complementary strengths: established companies bring regulatory expertise and manufacturing capabilities, while biotech firms offer innovative technologies and nimble research approaches. The synergy could accelerate the development pipeline and bring transformative therapies to market more rapidly. Lastly, we explore an intriguing development in personalized medicine. A team of researchers has unveiled an AI-driven platform designed to optimize drug regimens tailored specifically to individual patients' genetic profiles. By integrating genomic data with machine learning algorithms, this tool can predict patient-specific responses to various treatments and suggest optimal dosing strategies. This approach holds promise not only for enhancing therapeutic efficacy but also for minimizing adverse effects by accounting for individual variability in drug metabolism and response. As we continue to witness rapid advancements across various sectors of pharma and biotech, it's clear that innovation is at the forefront of transforming patient care and addressing some of the most challenging medical conditions of our time. Thank you for joining us today on Pharma Daily. Stay tuned for more updates on groundbreaking research and pivotal industry developments shaping healthcare's future landscape.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of remarkable advancements and strategic maneuvers that are shaping the future of drug development and patient care. Starting with Roche's breakthrough in oncology, their small molecule inhibitor, Divarasib, has shown promising results in a Phase 3 trial for patients with KRAS G12C-mutated non-small cell lung cancer. This trial demonstrated superior efficacy over competitors like Amgen's Lumakras and Bristol-Myers Squibb's Krazati. Historically, KRAS mutations have been difficult to target, but Divarasib's success underscores the potential of precision medicine in oncology. These findings could lead to more effective treatment options for NSCLC patients, showcasing how targeted therapies are revolutionizing cancer treatment by focusing on specific genetic mutations. In regulatory news, Vertex Pharmaceuticals has made significant strides with Casgevy (exagamglogene autotemcel), a gene therapy that now includes pediatric patients with sickle cell disease and transfusion-dependent beta thalassemia in its FDA-approved label. This marks a pivotal moment for gene therapy applications in blood disorders. Utilizing CRISPR technology, Vertex offers potentially curative solutions for debilitating conditions, signaling a new era where genetic disorders can be addressed at their root cause. Similarly, Novartis has gained European Commission approval for Itvisma to treat 5q spinal muscular atrophy in patients aged two years and older, further cementing gene therapies' role in mainstream medical practice. Strategic partnerships remain essential in driving innovation. Takeda's collaboration with Insilico Medicine on AI-driven drug discovery is a case in point. The $600 million partnership highlights the growing reliance on AI and machine learning to expedite therapeutic development processes. Platforms like Pharma.AI are being leveraged to identify novel drug candidates more efficiently. Additionally, AstraZeneca's alliance with CSPC Pharmaceutical Group to develop siRNA-based therapies for kidney diseases reflects the burgeoning interest in RNA therapeutics as these technologies open new avenues to address complex diseases. On the financial front, BridgeBio's ability to attract $1 billion in convertible preferred equity from Sixth Street and Healthcare Royalty underscores investor confidence in rare disease therapeutics. This funding will bolster its pipeline targeting cardiovascular and rare conditions, emphasizing the profitable potential found within niche markets of the pharmaceutical landscape. Manufacturing is also seeing expansion as Lonza deepens its partnership with an unnamed U.S. drugmaker to enhance biologics programs. Anticipated investments reaching into multi-billion Swiss Francs underscore the critical importance of robust manufacturing infrastructure to meet growing demands for biologics and antibody-drug conjugates. Clinical trials continue to yield promising results. Can-Fite Biopharma's Phase 2a trial for Namodenoson in treating advanced pancreatic ductal adenocarcinoma has shown promising survival data when combined with therapies targeting Wnt/β-catenin signaling pathways. At the same time, Otsuka's Phase 3 data for Voyxact (sibeprenlimab-szsi) demonstrated improved kidney function in patients with immunoglobulin A nephropathy, bolstering traditional FDA approval pathways. On the acquisitions front, GNI Group's acquisition of Ayumi Pharmaceutical for approximately JPY 44.8 billion highlights strategic moves to enhance global biopharma operations focusing on pain management solutions. Yet not all news is positive; Sanofi's Genzyme Ireland unit received an FDA warning letter regarding manufacturing violations related to Altuviiio production, pointing to ongoing regulatory challenges within production practices. Moving on to geopolitical considerations, recent congressional letters to major pharmaceutical CEOs have raised concerns about clinical trials conducted within China due to national security concerns. This tension illustrates the delicate balance between leveraging China's economic potential and safeguarding US interests—a critical issue as international collaborations continue to expand. Meanwhile, AstraZeneca's ongoing collaborations with CSPC Pharmaceutical Group further signify strategic bets on China's capabilities despite geopolitical tensions. Their joint efforts focus on kidney disease treatments while adding to existing agreements addressing obesity and chronic diseases. The FDA remains pivotal as key decisions anticipated this quarter could significantly influence investment strategies and research priorities. This includes revisiting applications previously delayed or rejected—decisions that could reshape industry dynamics. In conclusion, this dynamic landscape is marked by significant scientific breakthroughs and complex global interactions guiding pharmaceutical and biotech sectors toward a transformative era. Gene therapy advancements underscore progress in personalized medicine while geopolitical factors continue influencing strategic industry decisions. As regulatory bodies evolve their approaches alongside increasingly international partnerships, these developments collectively herald profound implications for drug development and patient care globally.Support the show

Farla Efros is a senior retail executive and former CEO who built and sold companies before facing her own breast cancer diagnosis. She brings that same operational mindset into a healthcare system that expects patients to manage complexity while they are at their most vulnerable.She was on a client call in Spain when the diagnosis came through. A clear mammogram had missed it. An MRI caught it. Within hours, she was ordering binders, building a plan, and structuring her treatment like a turnaround strategy. Every appointment became a meeting. Every doctor faced an agenda with dozens of questions. She paid out of pocket for PET scans that were denied and hired a third party firm to validate her treatment path when her own doctors resisted outside input. The conversation tracks what happens when a high-functioning executive enters a system built on delay, denial, and fragmentation. Efros describes negotiating for tests, managing physician relationships, and assembling an “executive board” of advisors across conventional and alternative care. She calls the experience “the worst client I ever had,” exposing how administrative burden shifts onto patients and families.The tension sits between what worked for her and what is inaccessible to most. Her approach requires confidence, time, and fluency in navigating power. The system rewards that behavior while quietly failing patients who cannot replicate it. Insurance coverage still left her paying out of pocket. Doctors pushed standard protocols over precision medicine. Survivorship offered little support once treatment ended.This episode examines how cancer care operates as a series of incentives rather than a coordinated system, and why patients are forced to become operators just to get through it.RELATED LINKSFarla EfrosFarla Efros on LinkedInF*ck CancerF*ck Cancer on AmazonAccentureCTOAMPULL QUOTES“I treated cancer like the worst client I ever had.”“They wouldn't approve the test, so I paid for it myself.”“Every appointment was a negotiation.”FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mike Switzer interviews Jessica Holdman, a reporter with the South Carolina Daily Gazette in Columbia, SC. Jessica tells us about the ports pausing activity at the Leatherman terminal and a GLP-1 pharma company in Aiken is expanding.

Today on DANGER CLOSE: THE FOURTH OPTION, I'm joined by Gerald Posner.Gerald is an investigative journalist, attorney, Pulitzer Prize finalist, and the author of thirteen books including CASE CLOSED, WHY AMERICA SLEPT, GOD'S BANKERS, and PHARMA.In this episode, we get into the pharmaceutical industry, the opioid crisis, the Sackler family, the JFK assassination and the conspiracy industry that grew in its aftermath, and the duty to follow the evidence wherever it leads.We also discuss how secrecy, power, money, and institutional failure shape public trust, and what it takes to stay focused on the facts.This is a companion podcast to my new thriller, THE FOURTH OPTION, talking to those on the front lines, analyzing modern warfare, and taking listeners deeper into the themes that inspired the novel.This podcast series is presented by HUXWRX Safety Co., Staccato 2011, and Bravo Company.Learn more about Gerald Posner: https://www.posner.com/Follow Gerald on Instagram: https://www.instagram.com/posnergram/Order: THE FOURTH OPTIONBooks by Gerald Posner:PHARMA: Greed, Lies, and the Poisoning of AmericaCASE CLOSEDGOD'S BANKERS: A History of Money and Power at the VaticanWHY AMERICA SLEPT: The Failure to Prevent 9/11

The evidence that someone planned Nancy Guthrie's kidnapping months in advance was everywhere online. Google Trends screenshots appearing to show searches for her Tucson address in June and Savannah Guthrie's salary in December. It looked damning. It circulated on every platform. People cited it as proof that whoever took Nancy had been researching her family's wealth for months. Then NewsNation reporter Brian Entin did something nobody else had bothered to do — he called Google. Google's answer: the search data as presented was not accurate. The searches as described didn't happen. The most-shared evidence of premeditation in the Nancy Guthrie case was not real. And it wasn't alone. A separate YouTube video fabricated Nancy's entire professional identity — placing her in Columbus, Ohio, calling her a pharmaceutical compliance officer, and building a 25-minute conspiracy about healthcare fraud retaliation. Nancy has never been a healthcare executive. She's never lived in Ohio. One search would have debunked it. Tony Brueski walks through both fabrications in detail and asks the question the internet never asked: what happens to a real investigation when manufactured evidence floods the system?Links:Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1Instagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/TrueCrimePodDisclaimer:This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.Hashtags:#NancyGuthrie #NancyGuthrieUpdate #TrueCrimeToday #FindingNancy #TrueCrime #GuthrieCase #NancyGuthrieDebunked #TrueCrimePodcast #SavannahGuthrie #NancyGuthrieFake

In 2020, Emily Mendenhall drove from Washington, DC to Okoboji, Iowa, a town of 800 that swells to 200,000 every summer, and walked into a pandemic that looked nothing like the one dominating national headlines. Inside gas stations and bars, masks marked you as an outsider. In one stop, a man told her family they would not be served if they kept theirs on. Her 6 year old daughter cried, confused. Mendenhall, a medical anthropologist at Georgetown University, did what she always does. She started asking questions. Over months, she interviewed neighbors, former classmates, and local officials, including her own brother in law who helped lead the local COVID response. The result became Unmasked, a case study in how community identity, economics, and politics shaped public health decisions in real time. That work led directly into her latest book, Invisible Illness: A History, from Hysteria to Long COVID, where she tracks a much older problem. Patients with chronic illness, especially women, often fail to meet medicine's demand for proof. Without a clear diagnosis, they lose access to care, insurance coverage, and legitimacy. Mendenhall argues that long COVID did not create this failure. It exposed it.This conversation centers on how healthcare systems reward certainty and punish complexity. Long COVID clinics send patients to 17 specialists without resolution. Insurance structures require diagnoses that many conditions cannot provide. Medical training still struggles to integrate trauma, mental health, and chronic disease into a coherent model of care.Mendenhall brings lived experience into the conversation. After COVID, she dealt with months of fatigue and escalating anxiety that altered her baseline health. She does not claim the label of long COVID, but she understands how quickly the system becomes harder to navigate once symptoms stop fitting clean categories. The stakes are not theoretical. In the United States, access to healthcare, disability benefits, and treatment still depends on whether a condition can be measured, coded, and reimbursed. For millions living with invisible illness, the burden of proof becomes the illness itself.RELATED LINKSEmily MendenhallInvisible Illness: A History, from Hysteria to Long COVIDScience PoliticsGeorgetown UniversityFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A YouTube video with hundreds of thousands of views claimed Nancy Guthrie was a pharmaceutical compliance officer from Columbus, Ohio, connected to a 32 billion dollar healthcare fraud conspiracy. The video stated it as fact. Professional narration. Graphics. The production quality of legitimate reporting. The problem: Nancy Guthrie was born in Fort Wright, Kentucky. She's lived in Tucson, Arizona for more than fifty years. She's a retired grandmother. She was never a compliance officer. She never lived in Ohio. The entire professional identity was fabricated. The theory that grew from it — that Nancy was a whistleblower silenced by corporate interests — was built on a foundation that doesn't exist. And a separate fabrication made it worse: manipulated Google Trends screenshots claiming someone in Arizona searched for Nancy's address months before the kidnapping. Google itself confirmed through Brian Entin at NewsNation that the data was not accurate. Two manufactured pieces of evidence. Two pillars of the case's online mythology. Both completely made up. Tony Brueski examines how the internet built an evidence factory around a real missing person — and why the content creators behind it are still collecting views.Links:Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1Instagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/TrueCrimePodDisclaimer:This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.Hashtags:#NancyGuthrie #NancyGuthrieUpdate #HiddenKillers #FindingNancy #TrueCrime #GuthrieCase #NancyGuthrieFraud #TrueCrimePodcast #SavannahGuthrie #TucsonCrime

New Guest Expert! On this week's Aftermath, Rebecca revisits the rise and fall of Crystal Pepsi with Professor Ernest Baskin. Chair of the Food, Pharma and Healthcare Department at Saint Joseph's University, Ernest shares some fascinating insights about the world of consumer market research, advertising and distribution tactics. Afterward, Patreon subscribers can join the post-interview discussion and revisit the board with Fact Checker Faryn Einhorn and Producer Clayton Early. Not part of the Patreon family yet? Click below and join us!Join our Patreon!Tell us who you think is to blame at http://thealarmistpodcast.comEmail us at thealarmistpodcast@gmail.comFollow us on Instagram @thealarmistpodcastFollow us on TikTok @thealarmistpodcastSupport this show http://supporter.acast.com/alarmist. Hosted on Acast. See acast.com/privacy for more information.

You can't scroll through your feed for five seconds without seeing someone talking about Ozempic, Wegovy, or the newest GLP-1 drug.But here's what nobody is telling you: your body was already designed to make its own version of this appetite-suppressing hormone. However, most of us have stopped feeding the good bacteria responsible for producing it.In this episode, I'm breaking down the gut-centric theory of hunger, a fascinating concept that completely changed the way I think about appetite, cravings, and weight management. Plus, I'll share what happened when I personally experimented with a specific category of food for my upcoming book and experienced something I can only describe as... injecting GLP-1. Without the injection.On this episode, you'll learn: The science behind what GLP-1 actually is (1:40)The real reason you feel like you can't stop eating (and what you can do to stop it) (4:33)All about the jaw-dropping Chinese study where volunteers minimized their hunger (9:03)Exactly which foods crank up your body's natural GLP-1 production (11:29)The one food category I added to my own diet that had me leaving half my meal on the plate (13:43)For the full episode transcript and show notes: https://drgundry.com/how-to-boost-glp1-naturally Thank you to our sponsors! Check them out: Take your water to the next level with the AquaTru water purifier, go to aquatruwater.com and enter code “GUNDRY20” at checkout for 20% off.Get $20 off your first box plus a free year of protein, like sirloin or ribeye at ButcherBox.com/GUNDRY.Visit Juvent.com/GUNDRY and use code GUNDRY at checkout to get an extra $300 off your Juvent Micro-Impact Platform.Get a quote today at Progressive.com.Shop my new air filter, Homekind Total Air! Use code CLEANAIR for 10% off. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.